<PAGE>
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934
FILED BY THE REGISTRANT /X/ FILED BY A PARTY OTHER THAN THE REGISTRANT / /
- --------------------------------------------------------------------------------
Check the appropriate box:
/X/ Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/ / Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to Section240.14a-11(c) or Section240.14a-12
THERMEDICS INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
THERMEDICS INC.
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
/ / No fee required.
/X/ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies: Common
Stock
-----------------------------------------------------------------------
2) Aggregate number of securities to which transaction applies: 4,880,553
-----------------------------------------------------------------------
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined): The filing
fee of $10,067 represents 1/50 of 1% of $50,330,703, which amount is
the value of the securities to be issued by the registrant as
consideration in the transaction (as calculated by multiplying the
average of the high and low prices of the registrant's common stock on
December 1, 1998 by the number of shares to be issued).
-----------------------------------------------------------------------
4) Proposed maximum aggregate value of transaction: $50,330,703
-----------------------------------------------------------------------
5) Total fee paid: $10,067
-----------------------------------------------------------------------
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
-----------------------------------------------------------------------
2) Form, Schedule or Registration Statement No.:
-----------------------------------------------------------------------
3) Filing Party:
-----------------------------------------------------------------------
4) Date Filed:
-----------------------------------------------------------------------
<PAGE>
THERMEDICS INC.
470 Wildwood Street
P.O. Box 2999
Woburn, Massachusetts 01888-1799
December , 1998
Dear Stockholder:
The enclosed Notice calls a Special Meeting of the Stockholders of
Thermedics Inc. I respectfully request all Stockholders to attend this meeting,
if possible.
Enclosed with this letter is a proxy authorizing three officers of the
Company to vote your shares for you if you do not attend the meeting. Whether or
not you are able to attend the meeting, I urge you to complete your proxy and
return it to our transfer agent, Bank Boston, N.A., in the enclosed addressed,
postage-paid envelope, as a quorum of the Stockholders must be present at the
meeting, either in person or by proxy.
I would appreciate your immediate attention to the mailing of this proxy.
Yours very truly,
John T. Keiser
PRESIDENT
<PAGE>
THERMEDICS INC.
470 Wildwood Street
P.O. Box 2999
Woburn, Massachusetts 01888-1799
NOTICE OF SPECIAL MEETING
December , 1998
To the Holders of the Common Stock of
THERMEDICS INC.
A Special Meeting of the Stockholders (the "Meeting") of Thermedics Inc.
(the "Company") will be held on Friday, January 22, 1999, at 10 a.m. at the
offices of Thermo Electron Corporation, 81 Wyman Street, Waltham, Massachusetts
02454. The purpose of the Meeting is to consider and vote upon a proposal to
approve the listing on the American Stock Exchange, Inc. of 4,880,553 shares of
the Company's common stock to be issued in connection with the acquisition of
TMO TCA Holdings Inc. from Thermo Electron Corporation pursuant to an Agreement
and Plan of Reorganization dated as of October 30, 1998. The sole asset of TMO
TCA Holdings Inc. is its ownership of 3,355,705 shares of common stock of the
Company's Thermo Cardiosystems Inc. subsidiary.
The transfer books of the Company will not be closed prior to the Meeting,
but, pursuant to appropriate action by the Board of Directors, the record date
for the determination of the Stockholders entitled to receive notice of and to
vote at the Meeting is November 27, 1998.
The By-laws require that the holders of a majority of the stock issued and
outstanding and entitled to vote be present or represented by proxy at the
Meeting in order to constitute a quorum for the transaction of business. It is
important that your shares be represented at the Meeting regardless of the
number of shares you may hold. Whether or not you are able to be present in
person, please sign and return promptly the enclosed proxy in the accompanying
envelope, which requires no postage if mailed in the United States.
This Notice, the proxy and proxy statement enclosed herewith are sent to you
by order of the Board of Directors.
SANDRA L. LAMBERT
CLERK
<PAGE>
PROXY STATEMENT
The enclosed proxy is solicited by the Board of Directors of Thermedics Inc.
(the "Company") for use at a Special Meeting of the Stockholders (the "Meeting")
to be held on Friday, January 22, 1999 at 10 a.m. local time at the offices of
Thermo Electron Corporation, 81 Wyman Street, Waltham, Massachusetts 02454, and
any adjournment thereof. The mailing address of the executive office of the
Company is 470 Wildwood Street, P.O. Box 2999, Woburn, Massachusetts 01888-1799,
and its telephone number is (781) 622-1000. This proxy statement and the
enclosed proxy were first furnished to Stockholders of the Company on or about
December , 1998.
VOTING PROCEDURES
The Board of Directors intends to present to the Meeting a proposal to
approve the listing on the American Stock Exchange, Inc. of 4,880,533 shares of
the Company's common stock, $.10 par value per share ("Common Stock"), to be
issued in connection with the acquisition by the Company of TMO TCA Holdings
Inc. from Thermo Electron Corporation ("Thermo Electron") pursuant to an
Agreement and Plan of Reorganization dated as of October 30, 1998, a copy of
which is attached hereto as Appendix A. The sole asset of TMO TCA Holdings Inc.
is its ownership of 3,355,705 shares of common stock of the Company's Thermo
Cardiosystems Inc. subsidiary.
The representation in person or by proxy of a majority of the outstanding
shares of Common Stock entitled to vote at the Meeting is necessary to provide a
quorum for the transaction of business at the Meeting. Shares can only be voted
if the Stockholder is present in person or is represented by returning a
properly signed proxy. Each Stockholder's vote is very important. Whether or not
you plan to attend the Meeting in person, please sign and promptly return the
enclosed proxy card, which requires no postage if mailed in the United States.
All signed and returned proxies will be counted towards establishing a quorum
for the Meeting, regardless of how the shares are voted. Proxies are being
solicited by the Company.
Shares represented by proxy will be voted in accordance with your
instructions. You may specify your choice by marking the appropriate box on the
proxy card. If your proxy card is signed and returned without specifying
choices, your shares will be voted for the management proposal and as the
individuals named as proxy holders on the proxy deem advisable on all other
matters as may properly come before the Meeting.
The affirmative vote of a majority of the shares present in person or
represented by proxy, and entitled to vote on the matter, is necessary for
approval of the management proposal. An instruction to abstain from voting on
the proposal will be treated as shares present and entitled to vote and, for
purposes of determining the outcome of the vote, will have the same effect as a
vote against the proposal. A broker "non-vote" occurs when a nominee holding
shares for a beneficial holder does not have discretionary voting power and does
not receive voting instructions from the beneficial owner. Broker "non-votes"
will not be treated as shares present and entitled to vote on a voting matter
and will have no effect on the outcome of the vote.
A Stockholder who returns a proxy may revoke it at any time before the
Stockholder's shares are voted at the Meeting by written notice to the Clerk of
the Company received prior to the Meeting, by executing and returning a later
dated proxy or by voting by ballot at the Meeting. Representatives of Arthur
Andersen LLP, the Company's independent public accountants since its inception,
are not expected to be present at the Meeting.
The outstanding stock of the Company entitled to vote (excluding shares held
in treasury by the Company) as of November 27, 1998 consisted of 36,810,227
shares of Common Stock. Only Stockholders of record at the close of business on
November 27, 1998 (the "Record Date") are entitled to vote at the Meeting. Each
share is entitled to one vote.
Thermo Electron has agreed to vote all of the shares of the Common Stock
held by it as of the Record Date in favor of the proposal and all matters
related thereto. As of the Record Date (without giving effect to the issuance of
the 4,880,533 shares contemplated by this proxy statement), Thermo Electron
beneficially owned approximately 67.7% of the outstanding Common Stock.
ACCORDINGLY, APPROVAL OF THE PROPOSAL BY THE STOCKHOLDERS OF THE COMPANY IS
ASSURED.
1
<PAGE>
PROPOSAL TO APPROVE THE LISTING OF SHARES ISSUABLE IN CONNECTION
WITH THE ACQUISITION OF TMO TCA HOLDINGS INC.
SUMMARY OF TRANSACTIONS CONTEMPLATED BY THE MERGER AGREEMENT
On October 30, 1998, the Company agreed issue 4,880,533 shares (the "TMD
Shares") of its Common Stock to Thermo Electron Corporation ("Thermo Electron")
in exchange for all of the issued and outstanding shares of TMO TCA Holdings
Inc. ("TCA Holdings"). TCA Holdings is the owner of 3,355,705 shares (the "TCA
Shares") of common stock of the Company's Thermo Cardiosystems Inc. subsidiary
("Thermo Cardiosystems"). The acquisition, which became legally effective on
, 1998, was made pursuant to an Agreement and Plan of Reorganization
dated as of October 30, 1998 (the "Merger Agreement"), among the Company, Cardio
Acquisition Inc., a wholly owned subsidiary of the Company ("Acquisition"),
Thermo Electron, and TCA Holdings, a wholly owned subsidiary of Thermo Electron.
Under the terms of the Merger Agreement, (i) Acquisition merged with and into
TCA Holdings, (ii) the outstanding shares of TCA Holdings' common stock were
canceled and converted into the right to receive the TMD Shares, (iii) each
outstanding share of Acquisition's common stock was canceled and converted into
one share of the common stock of TCA Holdings, and (iv) TCA Holdings became a
wholly owned subsidiary of the Company.
Approval of the Merger by the Stockholders of the Company is not required by
the Business Corporation Law of the Commonwealth of Massachusetts or by the
Company's Articles of Organization, as amended or By-Laws, as amended. However,
rules of the American Stock Exchange, Inc. (the "AMEX"), on which the Company's
Common Stock is listed for trading, require that the holders of a majority of
the Company's outstanding shares present and voting at a shareholders' meeting
approve the listing of the TMD Shares prior to their issuance. This approval is
required pursuant to Section 712 of the AMEX Company Guide, which requires
shareholder approval prior to the listing on the AMEX of shares to be issued as
partial consideration for an acquisition if (i) any substantial shareholder of
the listed company has a five percent or greater interest in the company to be
acquired and (ii) the issuance of the new shares could result in an increase in
the outstanding shares of the listed company of five percent or more. Thermo
Electron is a "substantial shareholder" of the Company and also has more than a
five percent interest in TCA Holdings. In addition, the issuance of the TMD
Shares in consideration of the Merger would result in an increase in the
Company's outstanding Common Stock of more than five percent. Thermo Electron
has agreed to vote all of the shares of the Company's Common Stock held by it as
of the record date of the Meeting (the "Record Date") in favor of the listing of
the TMD Shares and all matters related thereto. As of the Record Date, and
without giving effect to the issuance of the TMD Shares pursuant to the Merger
Agreement, Thermo Electron owned approximately 67.7% of the outstanding Common
Stock of the Company. After giving effect to the issuance of the TMD Shares
pursuant to the Merger Agreement, Thermo Electron would have owned approximately
80.9% of such Common Stock outstanding on the Record Date.
BACKGROUND OF THE MERGER AGREEMENT
The Company has several majority owned subsidiaries, including Thermo
Cardiosystems, a leader in the research, development and manufacture of
implantable left ventricular-assist systems. Thermo Electron owns all of the
stock of TCA Holdings, which in turn owns the TCA Shares. TCA Holdings had
acquired the TCA Shares in connection with Thermo Cardiosystems' acquisition of
International Technidyne Corporation ("ITC") from Thermo Electron on May 2,
1997. ITC is a leading manufacturer of near-patient, whole-blood coagulation
testing equipment and related disposables.
The Board of Directors of the Company has determined that it is the best
interests of the Company to acquire TCA Holdings in order to increase the
Company's ownership of Thermo Cardiosystems. On February 5, 1998, the Board of
Directors approved the acquisition of TCA Holdings.
2
<PAGE>
DETERMINATION OF THE CONSIDERATION ISSUABLE FOR TCA HOLDINGS
Under the terms of the Merger Agreement, the Company has agreed to issue the
TMD Shares to Thermo Electron in consideration of the acquisition of TCA
Holdings. The consideration to be paid for TCA Holdings was based on the
Company's determination of the fair market value of TCA Holding's sole asset,
its ownership of the TCA Shares. The fair market value of the TCA Shares was
determined based on the average of the closing prices of Thermo Cardiosystems'
common stock as reported on the AMEX for the five trading days ending on
February 4, 1998, the date prior to the date the Board of Directors of the
Company approved the acquisition. The number of shares of Common Stock to be
issued as consideration in the Merger was determined based on the average of the
closing prices of the Common Stock as reported on the AMEX for the same period.
Based on these calculations, it was determined that the consideration to be paid
for TCA Holdings was 4,880,533 shares of Common Stock with a value of
$75,587,000.
REASONS FOR THE MERGER/RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors believes that the acquisition of TCA Holdings was in
the best interests of the Company. The acquisition provided the Company with a
strategic opportunity to increase its ownership of Thermo Cardiosystems prior to
Thermo Cardiosystems commencing commercial sales of its implantable left
ventricular-assist systems. By increasing its ownership of Thermo Cardiosystems,
the Company reduces the minority interest in Thermo Cardiosystems and is able to
include a greater portion of Thermo Cardiosystems' net income in the Company's
consolidated results of operations. The Board of Directors also believes that
decreasing fractionalized ownership of Thermo Cardiosystems is in the best
interests of both the Company and Thermo Cardiosystems.
The Merger was structured to qualify as a tax-free reorganization in which
no gain or loss will be recognized by the Company in connection therewith. See
"Certain Federal Income Tax Consequences." Further, as the consideration to be
paid to Thermo Electron consists of Common Stock of the Company rather than
cash, the transaction will not impair the Company's working capital.
The Board of Directors has unanimously approved the Merger Agreement and the
transactions contemplated thereby and believes that the Merger is fair to and in
the best interests of the Company and its Stockholders. THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE IN FAVOR OF THE LISTING OF THE TMD
SHARES TO BE ISSUED IN CONNECTION WITH THE MERGER AGREEMENT.
SUMMARY OF THE MERGER AGREEMENT
GENERAL
On October 30, 1998, the Company, Acquisition, Thermo Electron and TCA
Holdings entered into the Merger Agreement, pursuant to which the Company
acquired TCA Holdings from Thermo Electron in exchange for the right to receive
the TMD Shares. Under the terms of the Merger Agreement (i) Acquisition merged
with and into TCA Holdings, (ii) outstanding shares of TCA Holdings' common
stock were canceled and converted into the right to receive the TMD Shares,
(iii) each outstanding share of Acquisition's common stock was canceled and
converted into one share of the common stock of TCA Holdings, and (iv) TCA
Holdings became a wholly owned subsidiary of the Company. See "Determination of
the Consideration Issuable for TCA Holdings," above for a discussion of the
valuation of the transaction.
EFFECTIVE DATE
The Merger became legally effective on December , 1998, upon the filing of
Articles of Merger with the Secretary of State of the Commonwealth of
Massachusetts pursuant to Section 78 of the Business Corporation Law of the
Commonwealth of Massachusetts.
3
<PAGE>
ISSUANCE OF THE SHARES
Upon the effective date of the Merger, all of the shares of TCA Holdings'
common stock, which were held by Thermo Electron, were canceled and converted
into the right to receive the TMD Shares. Thermo Electron's right to receive the
TMD Shares is conditioned only on the prior listing of the TMD Shares for
trading upon the AMEX. In the Merger Agreement, the Company agreed to take all
action necessary in accordance with applicable law to convene a meeting of its
Stockholders for the purpose of approving the listing of the TMD Shares for
trading upon the AMEX, and to recommend to the Stockholders the approval of such
listing. In the Merger Agreement, Thermo Electron agreed to vote all of the
shares of the Company's Common Stock held by it as of the record date of any
such meeting in favor of such listing. The Agreement provides that, in the event
that the Company is unable to obtain the approval of its Stockholders of the
listing of the TMD Shares on or before December 31, 1999, then, on December 31,
1999, the Company will pay to Thermo Electron the sum of $75,587,000 in cash in
lieu of issuing the TMD Shares.
As of the Record Date, and without giving effect to the issuance of the TMD
Shares pursuant to the Merger Agreement, Thermo Electron owned an aggregate of
approximately 67.7% of the outstanding Common Stock of the Company. After giving
effect to the issuance of the TMD Shares pursuant to the Merger Agreement,
Thermo Electron would have owned approximately 80.9% of such Common Stock
outstanding on the Record Date.
REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION
In the Merger Agreement, the Company and Acquisition, on the one hand, and
TCA Holdings and Thermo Electron, on the other hand, made certain
representations and warranties to one another with respect to certain customary
matters, such as their respective organization, their respective authority to
enter into the Merger Agreement and the enforceability of the Merger Agreement.
In addition, TCA Holdings and Thermo Electron made certain representations and
warranties to the Company with respect to (i) TCA Holdings' ownership of the TCA
Shares, (ii) the absence of liabilities of TCA Holdings, (iii) the absence of
any trade or business of TCA Holdings, (iv) certain tax matters and (v) other
matters requested by the Company's counsel. Each of these representations and
warranties survives the effectiveness of the Merger indefinitely. Each party has
agreed to indemnify the other for any damages the indemnified party suffers as a
result of breaches of such representations and warranties by the other party.
Notwithstanding this indemnification, the Company would be required to report as
an expense in its results of operations the full amount, including any
reimbursable amount, of any damages, with any indemnification payment it
receives from Thermo Electron being treated as a contribution to stockholders'
investment.
CERTAIN ADJUSTMENTS
The Merger Agreement provides that, in the event that the Company takes
certain actions (such as stock splits, recapitalizations and sales of
substantial portions of the Company's assets) prior to the date of issuance of
the TMD Shares (the "Payment Date"), then the number of shares of the Company's
Common Stock to be issued pursuant to the Merger will be adjusted as required to
put Thermo Electron in the same position as if the record date with respect to
any such transaction or transactions had been immediately after the Payment
Date, or otherwise to carry out the intents and purposes of the Merger
Agreement. Similarly, in the event that the Company declares any dividend or
other distribution in respect of the Company's Common Stock payable in cash or
other property other than in shares of Common Stock, then the TMD Shares to be
issued in connection with the Merger shall be deemed to be outstanding as of the
record date with respect to any such dividend or distribution, and the cash or
other property otherwise payable or distributable to Thermo Electron with
respect to such TMD Shares shall be held by the Company for the benefit of
Thermo Electron. Upon the issuance of the TMD Shares to Thermo Electron, such
cash or other property (together with any earnings or interest thereon) will
likewise be distributed by the Company to Thermo Electron.
4
<PAGE>
AMENDMENTS; WAIVERS
Any provision of the Merger Agreement may be amended or waived by the mutual
consent of the parties at any time.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
The Merger is intended to qualify as a tax-free reorganization under Section
368(a) of the Internal Revenue Code of 1986, as amended. Neither the Company nor
Thermo Electron intend to request a ruling from the Internal Revenue Service
with respect to the Merger. Assuming that the Merger is a tax-free
reorganization, no gain or loss will be recognized by the Company in connection
with the Merger.
REGULATORY APPROVALS
No federal or state regulatory approvals are required in order to issue the
TMD Shares pursuant to the Merger Agreement.
NO DISSENTERS' APPRAISAL RIGHTS
Under applicable provisions of the Business Corporation Law of the
Commonwealth of Massachusetts, holders of the Company's Common Stock will not
have any dissenters' appraisal rights in connection with the listing of the TMD
Shares.
INFORMATION CONCERNING TMO TCA HOLDINGS INC.
Under the terms of the Merger Agreement, the Company has acquired all of the
issued and outstanding shares of capital stock of TCA Holdings, a wholly owned
subsidiary of Thermo Electron, in exchange for the right to receive the TMD
Shares. TCA Holdings was incorporated on February 2, 1998 and its principal
executive office is located at 81 Wyman Street, Waltham, Massachusetts 02454.
BUSINESS
TCA Holdings is the owner of the TCA Shares. Thermo Cardiosystems, which is
a majority owned subsidiary of the Company, is a leader in the research,
development and manufacture of implantable left ventricular-assist systems. All
of such TCA Shares are owned free and clear of any charges, liens, encumbrances,
security interests or adverse claims. There are no shareholder agreements,
voting trusts, proxies or other agreements, instruments or understandings with
respect to the voting of the TCA Shares.
Other than the TCA Shares, TCA Holdings does not own, lease or use, directly
or indirectly, any assets or other property, whether real or personal, tangible
or intangible. TCA Holdings does not, directly or indirectly, own any equity
interest in any corporation, partnership joint venture or other entity. TCA
Holdings does not engage, and since its organization has not engaged, in any
trade or business, and it has no liabilities or obligations of any nature,
whether accrued, absolute, contingent or otherwise. TCA Holdings does not have,
nor has it ever had, any employees.
MANAGEMENT
John N. Hatsopoulos, 63, is President and sole director of TCA Holdings. In
addition, Mr. Hatsopoulos has been a director of the Company since March 1995.
Mr. Hatsopoulos was chairman of the board of the Company from March 1995 to
March 1998. He has served as the Company's chief financial officer since 1988
and its senior vice president since December 1997. He was a vice president of
the Company from 1986 through December 1997. Mr. Hatsopoulos has been the chief
financial officer of Thermo Electron since January 1988. In September 1998, Mr.
Hatsopoulos announced his retirement from this position, as well as from the
positions of chief financial officer and senior vice president of the Company,
effective December 31, 1998. In addition, Mr. Hatsopoulos served as President of
Thermo
5
<PAGE>
Electron from January 1997 to September 1998 and as an executive vice president
of Thermo Electron from 1986 to January 1997. Mr. Hatsopoulos has served as a
director of Thermo Electron since September 1997 and was appointed vice chairman
of the board of directors of Thermo Electron in September 1998. Mr. Hatsopoulos
is also a director of LOIS/USA Inc., Thermo Ecotek Corporation, Thermo Fibertek
Inc., Thermo Instrument Systems Inc., Thermo Power Corporation and Thermo
TerraTech Inc.
INFORMATION CONCERNING THE COMPANY
MARKET FOR COMPANY'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS
The Company's Common Stock is publicly traded on the AMEX. The following
sets forth, for the fiscal periods indicated, the high and low sales prices as
reported in the consolidated transaction reporting system.
<TABLE>
<CAPTION>
HIGH LOW
--------- ---------
<S> <C> <C>
FISCAL 1995
First Quarter........................................................... $17 1/8 $12 3/4
Second Quarter.......................................................... 19 7/8 15 5/8
Third Quarter........................................................... 21 1/2 18 1/8
Fourth Quarter.......................................................... 27 1/2 17 3/4
FISCAL 1996
First Quarter........................................................... 29 7/8 23 5/8
Second Quarter.......................................................... 31 3/4 24 7/8
Third Quarter........................................................... 28 3/4 20 3/4
Fourth Quarter.......................................................... 26 3/8 18
FISCAL 1997
First Quarter........................................................... 21 1/8 16 7/8
Second Quarter.......................................................... 19 15
Third Quarter........................................................... 19 9/16 15 11/16
Fourth Quarter.......................................................... 20 3/16 15 1/16
FISCAL 1998
First Quarter........................................................... 17 13/16 14 15/16
Second Quarter.......................................................... 17 1/2 12 3/8
Third Quarter........................................................... 12 13/16 7 7/16
Fourth Quarter (through November 27, 1998).............................. 10 3/8 10 1/8
</TABLE>
The high, low and closing prices of the Company's Common Stock on the AMEX
on February 4, 1998, the date prior to the date the Board of Directors of the
Company approved the Merger were $16, $15 3/16 and $16, respectively. On
November 27, 1998 the closing price of the Common Stock on the AMEX was $10 5/16
per share. There were 2,149 holders of Common Stock of record as of November 27,
1998. Holders of Common Stock do not have any preemptive rights to subscribe for
additional issuances of Common Stock or securities convertible into Common
Stock.
The Company has never paid any cash dividends because its policy is to use
earnings to finance expansion and growth. The Company's Board of Directors
anticipates that for the foreseeable future no cash dividends will be paid on
the Company's Common Stock.
6
<PAGE>
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (IN THOUSANDS EXCEPT PER SHARE
AMOUNTS)
<TABLE>
<CAPTION>
1998
-------------------------------
FIRST SECOND THIRD
--------- --------- ---------
<S> <C> <C> <C>
Revenues......................................................................... $ 75,611 $ 76,711 $ 81,515
Gross Profit..................................................................... 37,000 37,839 37,454
Income Before Extraordinary Item................................................. 5,368 5,274 4,278
Net Income....................................................................... 6,573 8,707 4,278
Earnings per Share Before Extraordinary Item:
Basic.......................................................................... .13 .13 .10
Diluted........................................................................ .13 .12 .10
Earnings per Share:
Basic.......................................................................... .16 .21 .10
Diluted........................................................................ .16 .20 .10
</TABLE>
<TABLE>
<CAPTION>
1997
------------------------------------------
<S> <C> <C> <C> <C>
FIRST SECOND THIRD FOURTH
--------- --------- --------- ---------
Revenues.............................................................. $ 72,057 $ 75,996 $ 76,217 $ 83,396
Gross Profit.......................................................... 35,096 37,856 37,784 41,250
Net Income............................................................ 21,966 5,506 6,664 7,356
Earnings per Share:
Basic............................................................... .60 .15 .18 .20
Diluted............................................................. .56 .14 .17 .19
</TABLE>
<TABLE>
<CAPTION>
1996
------------------------------------------
<S> <C> <C> <C> <C>
FIRST SECOND THIRD FOURTH
--------- --------- --------- ---------
Revenues.............................................................. $ 68,994 $ 71,094 $ 74,202 $ 77,787
Gross Profit.......................................................... 33,185 34,121 37,668 38,966
Net Income............................................................ 5,257 9,754 6,359 7,768
Earnings per Share:
Basic............................................................... .15 .27 .17 .21
Diluted............................................................. .14 .25 .16 .20
</TABLE>
7
<PAGE>
SELECTED FINANCIAL INFORMATION
The selected financial information included below for the Company as of and
for the fiscal years ended January 3, 1998, and December 28, 1996, and for the
fiscal year ended December 30, 1995, has been derived from the Company's
Consolidated Financial Statements, which have been audited by Arthur Andersen
LLP, independent public accountants, as indicated in their report incorporated
by reference herein. The selected financial information as of December 30, 1995,
and as of and for the fiscal years ended December 31, 1994, and January 1, 1994,
has been derived from the Company's Consolidated Financial Statements, which
have been audited by Arthur Andersen LLP, but have not been included in this
Proxy Statement or incorporated by reference herein. The selected financial
information as of and for the nine months ended October 3, 1998, and September
27, 1997, has not been audited but, in the opinion of the Company, includes all
adjustments (consisting only of normal, recurring adjustments) necessary to
present fairly such information in accordance with generally accepted accounting
principles applied on a consistent basis. The results of operations for the nine
months ended October 3, 1998, are not necessarily indicative of results for the
entire year.
<TABLE>
<CAPTION>
NINE MONTHS ENDED
-------------------------- FISCAL YEAR
OCTOBER 3, SEPTEMBER 27, -----------------------------------------------------
1998 1997 1997 1996 1995 1994 1993
----------- ------------- --------- --------- --------- --------- ---------
<S> <C> <C> <C> <C> <C> <C> <C>
(IN THOUSANDS EXCEPT PER SHARE AMOUNTS)
STATEMENT OF INCOME DATA:
Revenues.......................... $ 233,887 $ 224,270 $ 307,666 $ 292,077 $ 208,041 $ 183,753 $ 104,545
----------- ------------- --------- --------- --------- --------- ---------
Costs and Operating Expenses:
Cost of revenues................ 121,594 113,534 155,680 148,137 110,935 99,328 56,484
Selling, general, and
administrative
expenses...................... 66,671 63,851 86,308 85,045 55,951 49,813 28,614
Research and development
expenses...................... 19,543 17,752 24,270 21,363 14,874 14,143 9,212
Nonrecurring costs.............. -- -- -- 17,637 -- -- --
----------- ------------- --------- --------- --------- --------- ---------
207,808 195,137 266,258 272,182 181,760 163,284 94,310
----------- ------------- --------- --------- --------- --------- ---------
Operating Income.................. 26,079 29,133 41,408 19,895 26,281 20,469 10,235
Interest and Other Income, Net.... 6,009 7,715 10,414 7,951 5,831 4,989 4,582
Gain on Issuance of Stock by
Subsidiaries.................... -- 17,075 17,075 23,651 3,455 -- --
----------- ------------- --------- --------- --------- --------- ---------
Income Before Provision for Income
Taxes, Minority Interest, and
Extraordinary Item.............. 32,088 53,923 68,897 51,497 35,567 25,458 14,817
Provision for Income Taxes........ 12,604 14,391 19,675 13,969 11,781 9,680 5,862
Minority Interest Expense......... 4,564 5,396 7,730 8,390 6,612 3,083 1,322
----------- ------------- --------- --------- --------- --------- ---------
Income Before Extraordinary
Item............................ 14,920 34,136 41,492 29,138 17,174 12,695 7,633
Extraordinary Item, Net of
Provision for Income Taxes...... 4,638 -- -- -- -- -- --
----------- ------------- --------- --------- --------- --------- ---------
Net Income........................ $ 19,558 $ 34,136 $ 41,492 $ 29,138 $ 17,174 $ 12,695 $ 7,633
----------- ------------- --------- --------- --------- --------- ---------
----------- ------------- --------- --------- --------- --------- ---------
Earnings per Share:
Basic........................... $ .48 $ .93 $ 1.13 $ .80 $ .51 $ .39 $ .25
----------- ------------- --------- --------- --------- --------- ---------
----------- ------------- --------- --------- --------- --------- ---------
Diluted......................... $ .46 $ .88 $ 1.07 $ .75 $ .48 $ .38 $ .25
----------- ------------- --------- --------- --------- --------- ---------
----------- ------------- --------- --------- --------- --------- ---------
Weighted Average Shares:
Basic........................... 41,065 36,695 36,700 36,417 33,660 32,878 30,291
----------- ------------- --------- --------- --------- --------- ---------
----------- ------------- --------- --------- --------- --------- ---------
Diluted......................... 43,061 38,913 38,911 38,202 35,036 33,108 30,509
----------- ------------- --------- --------- --------- --------- ---------
----------- ------------- --------- --------- --------- --------- ---------
BALANCE SHEET DATA (AT END OF
PERIOD):
Working Capital................... $ 232,596 $ 289,325 $ 309,363 $ 208,170 $ 114,340 $ 131,578 $ 135,992
Total Assets...................... 559,019 535,601 536,552 456,699 386,249 306,691 251,874
Long-term Obligations............. 122,678 143,464 142,771 74,359 45,201 82,551 59,130
Shareholders' Investment.......... 243,608 220,596 227,346 211,582 172,751 136,783 122,186
</TABLE>
8
<PAGE>
FORWARD-LOOKING STATEMENTS
In connection with the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, the Company wishes to caution readers that the
following important factors, among others, in some cases have affected, and in
the future could affect, the Company's actual results and could cause its actual
results in 1998 and beyond to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, the Company.
RISKS ASSOCIATED WITH ACQUISITION STRATEGY. The Company's strategy includes
the acquisition of businesses and technologies that complement or augment its
existing product lines. Promising acquisitions are difficult to identify and
complete for a number of reasons, including competition among prospective buyers
and the need for regulatory approval, including antitrust approvals. There can
be no assurance that the Company will be able to complete future acquisitions or
that it will be able to successfully integrate any acquired business. In order
to finance such acquisitions, it may be necessary for the Company to raise
additional funds through public or private financings. Any equity or debt
financing, if available at all, may be on terms which are not favorable to the
Company and, in the case of equity financing, may result in dilution to the
Company's stockholders.
RISKS ASSOCIATED WITH SPIN-OUT OF SUBSIDIARIES. The Company has adopted a
strategy of spinning out certain of its businesses into separate subsidiaries
and having these subsidiaries sell a minority interest to outside investors. As
a result of the sale of stock by subsidiaries, the issuance of stock by
subsidiaries upon conversion of convertible debentures and similar transactions,
the Company records gains that represent the increase in the Company's net
investment in the subsidiaries. These gains have represented a substantial
portion of the net income reported by the Company in certain periods. The size
and timing of these transactions are dependent on market and other conditions
that are beyond the Company's control. Accordingly, there can be no assurance
that the Company will be able to generate gains from such transactions in the
future.
In addition, in October 1995, the Financial Accounting Standards Board
("FASB") issued an exposure draft of a Proposed Statement of Financial
Accounting Standards, "Consolidated Financial Statements: Policy and Procedures"
(the "Proposed Statement"). The Proposed Statement would establish new rules for
how consolidated financial statements should be prepared. If the Proposed
Statement is adopted, there could be significant changes in the way the Company
records certain transactions of its controlled subsidiaries. Among those
changes, any sale of the stock of a subsidiary that does not result in a loss of
control would be accounted for as a transaction in equity of the consolidated
entity with no gain or loss being recorded. The exposure draft addresses the
consolidation issues in two parts: consolidation procedures, which includes
proposed rule changes affecting the Company's ability to recognize gains on
issuances of subsidiary stock, and consolidation policy, which does not address
accounting for such gains. During 1997, the FASB decided to focus its efforts on
the consolidation policy part of the exposure draft and to consider resuming
discussion on consolidation procedures after completion of the efforts on
consolidation policy. The timing and content of any final statement are
uncertain.
INTERNATIONAL OPERATIONS. Sales outside the U.S. have accounted for a
significant percentage of the Company's total revenues. The Company intends to
continue to expand its presence in international markets. International sales
are subject to a number of risks, including the following: agreements may be
difficult to enforce and receivables difficult to collect through a foreign
country's legal system; foreign customers may have longer payment cycles;
foreign countries may impose additional withholding taxes or otherwise tax the
Company's foreign income, impose tariffs, or adopt other restrictions on foreign
trade; fluctuations in exchange rates may affect product demand and adversely
affect the profitability in U.S. dollars of products and services provided by
the Company in foreign markets where payment for the Company's products and
services is made in the local currency; U.S. export licenses may be difficult to
obtain; and the protection of intellectual property in foreign countries may be
more difficult to enforce. There can be no assurance that any of these factors
will not have a material adverse effect on the
9
<PAGE>
Company's business and results of operations. During fiscal year 1997, the
Company had exports from its U.S. and foreign operations to Asia of
approximately 8% of total revenues. Exports to Asia in fiscal year 1997 were
primarily to Japan, China, and South Korea. Asia is experiencing a severe
economic crisis, which has been characterized by sharply reduced economic
activity and liquidity, highly volatile foreign-currency-exchange and interest
rates, and unstable stock markets. The Company's export sales could be adversely
affected by the unstable economic conditions in Asia.
TECHNOLOGICAL CHANGE AND COMPETITION. The market for many of the Company's
products is characterized by changing technology, evolving industry standards,
and new product introductions. The Company's future success will depend, in
part, upon its ability to enhance its existing products and to develop and
introduce new products and technologies to meet changing customer requirements.
The Company is currently devoting significant resources toward the enhancement
of its existing products and the development of new products and technologies.
There can be no assurance that the Company will successfully complete the
enhancement and development of these products in a timely fashion, or that these
products will compete successfully with those of the Company's competitors. The
Company is aware of one other company that has received premarket approval from
the FDA for an implantable LVAS that competes with the Company's LVAS. Certain
of the Company's competitors, including its competitor in the implantable LVAS
market, have greater resources, manufacturing and marketing capabilities,
technical staff, and production facilities than those of the Company. As a
result, they may be able to adapt more quickly to new or emerging technologies
and changes in customer requirements, or to devote greater resources to the
promotion and sale of their products than can the Company. Competition could
increase if new companies enter the market, or if existing competitors expand
their product lines.
INTELLECTUAL PROPERTY RIGHTS. The Company relies upon trade secret
protection and patents to protect its proprietary rights. There can be no
assurance that patents will issue from any pending or future patent applications
owned by or licensed to the Company, or that the claims allowed under any issued
patents will be sufficiently broad to protect the Company's technology. In the
absence of patent protection, the Company may be vulnerable to competitors who
attempt to copy the Company's products or gain access to its trade secrets and
know-how. Proceedings initiated by the Company to protect its proprietary rights
could result in substantial costs to the Company. The Company has received
correspondence from a third party alleging that the textured surface of the left
ventricular-assist systems ("LVAS") infringes certain patent rights of such
third party. The Company believes that it has meritorious defenses to the claims
of the third party. However, no assurance can be given that the Company would be
successful if litigation were commenced or that others will not claim that the
Company infringes their intellectual property rights. There can be no assurance
that competitors of the Company will not initiate litigation to challenge the
validity of the Company's patents, or that they will not use their resources to
design comparable products that do not infringe the Company's patents. There may
also be pending or issued patents held by parties not affiliated with the
Company that relate to the Company's products or technologies. The Company may
need to acquire licenses to, or contest the validity of, any such patents. There
can be no assurance that any license required under any such patent would be
made available on acceptable terms, or that the Company would prevail in any
such contest. The Company could incur substantial costs in defending itself in
suits brought against it, or in suits in which the Company may assert its patent
rights against others. If the outcome of any such litigation is unfavorable to
the Company, the Company's business and results of operations could be
materially adversely affected. In addition, the Company relies on trade secrets
and proprietary know-how which it seeks to protect, in part, by confidentiality
agreements with its collaborators, employees, and consultants. There can be no
assurance that these agreements will not be breached, that the Company would
have adequate remedies for any breach, or that the Company's trade secrets will
not otherwise become known or be independently developed by competitors.
UNCERTAINTY OF REGULATORY APPROVAL FOR BIOMEDICAL DEVICES. Thermo
Cardiosystems' biomedical devices, including its LVAS, are subject to approval
by the U.S. Food and Drug Administration ("FDA") before commercial sale of such
devices may commence in the U.S. Thermo Cardiosystems is also subject to
10
<PAGE>
regulatory requirements in foreign countries in which Thermo Cardiosystems
markets its devices. The process of obtaining regulatory approvals is lengthy,
expensive, and inherently uncertain. Even after FDA and other regulatory
approvals have been obtained, such approvals can be suspended or revoked if
Thermo Cardiosystems' products do not continue to satisfy regulatory
requirements. Failure to comply with applicable regulatory requirements can
result in, among other things, fines, suspensions of approvals, recalls of
products, operating restrictions, and criminal prosecutions.
In October 1994, Thermo Cardiosystems received FDA approval for the
commercial sale of its pneumatic LVAS. In April 1994, Thermo Cardiosystems
received the CE Mark for commercial sale of the pneumatic LVAS in all European
Union countries. Thermo Cardiosystems' HeartPak-TM- portable console received
the CE Mark in February 1995 and the HeartPak is currently in Phase I clinical
trials in the U.S. In September 1998, Thermo Cardiosystems' electric LVAS
received premarket approval by the FDA for use as a bridge to transplant. The
electric LVAS received the CE Mark in August 1995 for use as a bridge to
transplant and as an alternative to transplant. Thermo Cardiosystems' electric
LVAS is currently in use in clinical trials in the U.S. testing the safety and
efficacy of the device as an alternative to transplant.
Significant design changes to Thermo Cardiosystems' LVAS, including use of
the portable console for the pneumatic LVAS, must be approved pursuant to a
supplement to an approved PMA application. Failure of Thermo Cardiosystems to
obtain FDA approval for the commercial sale of the electric LVAS as an
alternative to transplant would have a material adverse effect on Thermo
Cardiosystems' long-term growth prospects. In addition, failure of Thermo
Cardiosystems to obtain approval for the HeartPak portable console would likely
require patients supported by the pneumatic LVAS to remain hospitalized. This
could materially restrict the market for the pneumatic LVAS.
UNCERTAINTY OF PATIENT REIMBURSEMENT. The cost of implanting a cardiac
support system is substantial. In addition, Thermo Cardiosystems' coagulation
testing equipment can cost several thousand dollars per instrument. Without the
financial support of the government or third-party insurers, the market for
Thermo Cardiosystems' devices and equipment will be limited. Medicare and
Medicaid limit the reimbursement that U.S. hospitals receive for treating
certain medical conditions by setting maximum fees that can be charged to their
patients. Under these systems, hospitals are paid a fixed amount for treating
each patient with a particular diagnosis. Private insurers also have initiated
reimbursement systems designed to slow the escalation of healthcare costs. In
addition, the federal government is considering, and certain state governments
are considering or have adopted, new healthcare policies intended to curb rising
costs. Such policies include rationing of government-funded reimbursement for
healthcare services and imposing price controls upon providers of medical
products and services. These policies could have the effect of limiting the
availability of reimbursement for procedures, such as the implantation of an
LVAS, that involve prolonged treatment of critically ill patients.
In November 1995, the U.S. Health Care Finance Administration ("HCFA")
issued a decision that extends Medicare coverage to LVAS devices used as a
bridge to heart transplant, which fulfill certain Medicare coverage criteria.
This decision, updated in April 1998, has applied to Thermo Cardiosystems'
pneumatic LVAS and is expected to extend to the electric LVAS. Several major
non-government insurers have also agreed to offer coverage for LVAS devices.
This coverage has been applied to the pneumatic LVAS and is expected to extend
to the electric LVAS; however, no assurance can be given that third party payers
will cover the electric LVAS immediately because of the device's intended
out-patient use. Even though reimbursement has been established by HCFA and by
certain non-government insurers for LVAS devices, the Medicare coverage criteria
could be amended or revised by HCFA, the amount of available reimbursement may
change, and reimbursement may be denied by an insurer under certain
circumstances, including if it is determined that a procedure was not the most
cost-effective treatment method, was experimental, or was used for an unapproved
indication. No assurance can be given that additional third-party reimbursement
for the LVAS devices will be granted within a reasonable period of time, or at
all. The unavailability of third-party reimbursement for procedures involving
Thermo Cardiosystems' systems or for
11
<PAGE>
Thermo Cardiosystems' biomedical devices would have a material adverse effect on
the Company's business.
UNCERTAINTY OF OPINION LEADER ACCEPTANCE AND SUPPORT. A limited number of
cardiac surgeons and cardiologists influence medical device selection and
purchase decisions for a large portion of the target patient population. The
Company will achieve its business objectives only if its LVAS are recommended
for use by such opinion leaders. In addition, acceptance by these physicians of
Thermo Cardiosystems' whole-blood coagulation monitoring systems and Coumadin
monitors is also important to the success of Thermo Cardiosystems' business.
Thermo Cardiosystems has developed working relationships with a number of
leading medical centers, and its existing and proposed LVAS and its blood
coagulation monitoring systems have been well received by opinion leaders in
cardiac surgery and cardiology. Moreover, since the inception of its work on
cardiac support systems in 1966, Thermo Cardiosystems has relied upon surgical
teams at medical institutions to perform clinical trials that are necessary for
obtaining FDA approvals. A continuing working relationship with those and other
institutions will be important to the success of Thermo Cardiosystems. No
assurance can be given that existing relationships and arrangements can be
maintained or that new relationships will be established. Furthermore, economic,
psychological, ethical, and other concerns may limit acceptance of heart-assist
devices in general, and there can be no assurance that markets of sufficient
size will develop for Thermo Cardiosystems' LVAS.
AVAILABILITY OF COMPONENTS AND RAW MATERIALS. Thermo Cardiosystems relies
on a number of custom-designed components and materials supplied by other
companies to manufacture its LVAS. Thermo Cardiosystems is making efforts to
minimize the risks associated with sole sources and ensure long-term
availability, including qualifying alternative materials and components or
developing alternative sources for materials and components supplied by a single
source. Although the Company believes that it has adequate supplies of materials
and components to meet demand for its products for the foreseeable future, no
assurance can be given that Thermo Cardiosystems will not experience shortages
of certain materials or components in the future that could delay shipments of
its products. The cost to Thermo Cardiosystems to evaluate and test alternative
materials and components and the time necessary to obtain FDA approval for these
materials are inherently difficult to determine because both time and cost are
dependent on at least two factors: the similarity of the alternative material or
component to the original material or component, and the amount of third-party
testing that may have already been completed on alternative materials or
components. There can be no assurance that the substitution of alternative
materials or components would not cause delays in Thermo Cardiosystems' LVAS
development programs or adversely affect the Company's ability to manufacture
and ship LVAS to meet demand.
LIMITED MANUFACTURING AND MARKETING EXPERIENCE OF THERMO
CARDIOSYSTEMS. Prior to FDA approval of commercial sale of the pneumatic LVAS,
Thermo Cardiosystems' LVAS business was engaged only in research and
development. Since that time, Thermo Cardiosystems has been building its
manufacturing, marketing, and sales capabilities. Although Thermo Cardiosystems
has not experienced difficulties in manufacturing its LVAS at volume, cost, and
quality levels sufficient to satisfy the increased demand resulting from
commercial approval, no assurance can be given that Thermo Cardiosystems will
not encounter difficulties as sales volumes increase or new products and/or
components are approved for commercial sale. Thermo Cardiosystems does not have
experience in the large-scale commercialization of LVAS medical devices.
Although Thermo Cardiosystems has added sales and marketing staff and is
expanding its distribution capabilities worldwide, no assurance can be given
that Thermo Cardiosystems will be able to market and sell its LVAS products
successfully in high volumes.
PRODUCT LIABILITY. Thermo Cardiosystems faces an inherent business risk of
exposure to product liability claims relating to the use of its products.
Although Thermo Cardiosystems currently maintains product liability insurance
against this risk, there can be no assurance that it will continue to be able to
obtain such coverage at economically feasible rates, if at all, or that such
coverage will be adequate in
12
<PAGE>
terms and scope to completely protect Thermo Cardiosystems in the event of a
successful product liability claim.
EFFECT OF GOVERNMENT REGULATIONS AND APPROVALS ON MARKET FOR THERMO
SENTRON'S PRODUCTS. The market for certain of the Company's Thermo Sentron Inc.
("Thermo Sentron") subsidiary's products, both in the United States and abroad,
is subject to or influenced by various domestic and foreign clean air and
consumer protection laws. Thermo Sentron designs, develops, and markets its
products to meet customer needs created by existing and anticipated regulations,
and any changes in these regulations may adversely affect consumer demand for
Thermo Sentron's products. In addition, the marketing of certain of Thermo
Sentron's products is dependent upon the receipt of regulatory and other
approvals, including industry association approvals of the design, construction,
and accuracy of Thermo Sentron's products. Delays in obtaining, or the failure
to obtain, any such approvals could have a material adverse effect on Thermo
Sentron's business and results of operations.
EFFECT OF ELECTRICAL STANDARDS ON DEMAND FOR THERMO VOLTEK'S
PRODUCTS. Demand for the Company's Thermo Voltek Corp. ("Thermo Voltek")
subsidiary's electromagnetic compatibility ("EMC") testing products and services
is driven to a large extent by mandatory government standards and voluntary
industry standards relating to electromagnetic compatibility. In particular,
demand for many of Thermo Voltek's products results from efforts by
manufacturers to comply with IEC 801, the European Union directive that became
effective on January 1, 1996. As the number of noncomplying manufacturers is
reduced over time, demand for Thermo Voltek's products is likely to be adversely
affected. In addition, if new EMC standards requiring new testing capabilities
are enacted less frequently or if EMC standards become less strict or not
strictly enforced, demand for Thermo Voltek's products could be adversely
affected.
DEPENDENCE OF EXPLOSIVES-DETECTION MARKET ON GOVERNMENT REGULATION AND
AIRLINE INDUSTRY. The Company's Thermedics Detection Inc. ("Thermedics
Detection") subsidiary's sales of its explosives-detection systems for use in
airports has been and will continue to be dependent on governmental initiatives
to require, or support, the screening of checked luggage, carry-on items and
personnel with advanced explosives-detection equipment. Substantially all of
such systems have been installed at airports in countries other than the United
States, in which the applicable government or regulatory authority overseeing
the operations of the airport has mandated such screening. Such mandates are
influenced by many factors outside of the control of Thermedics Detection,
including political and budgetary concerns of governments, airlines, and
airports. Of the more than 600 commercial airports worldwide, more than 400 are
located in the United States. Accordingly, Thermedics Detection believes that
the size of the market for explosives-detection equipment is, and will
increasingly be, significantly influenced by United States government
regulation. In the United States, the Aviation Security Act of 1990 directed the
Federal Aviation Administration (the "FAA") to develop a standard for
explosives-detection systems and required airports in the United States to
deploy systems meeting this standard in 1993. To date, no system has
demonstrated that it meets all FAA standards under realistic airport operating
conditions. As a result, the FAA has not mandated the installation of automated
explosives-detection systems, and only a limited number of these systems have
been deployed in the United States. The FAA first certified a computed X-ray
tomography system for checked luggage in December 1994. Thermedics Detection's
systems are trace detectors for which no FAA certification process for checked
baggage, carry-on, or personal screening exists to date. Currently, Thermedics
Detection is seeking FAA approval for its EGIS and EGIS II systems for use by
airlines in screening carry-on electronic items and luggage searches. There can
be no assurance, however, that such FAA approvals will be obtained. Each airline
must seek this approval for each application. Although the FAA has provided
significant funding to Thermedics Detection in connection with the development
of its explosives-detection technology, there can be no assurance that any of
Thermedics Detection's systems will ever meet this or any other United States
certification standard. Any product utilizing a technology ultimately
recommended or required by the FAA will have a significant competitive advantage
in the market for explosives-detection devices. Unless the FAA takes action with
13
<PAGE>
respect to a particular explosives-detection product or technology, airlines
will not be required to purchase or upgrade their security systems, including
upgrading existing metal-detection equipment. Earnings of U.S. air carriers
tends to fluctuate significantly from time to time. Any depression in the
financial condition of such carriers would likely result in lower capital
spending for discretionary items. Moreover, there can be no assurance that
additional countries will mandate the implementation of effective explosives
screening for airline baggage, carry-on items or personnel, or that, if
mandated, Thermedics Detection's systems will meet the certification or other
requirements of the applicable government authority. Even if Thermedics
Detection's systems were to meet the applicable requirements, there can be no
assurance that Thermedics Detection would be able to market its systems
effectively.
In October 1996, the United States enacted legislation which includes a
$144.2 million allocation to purchase explosives-detection systems and other
advanced security equipment, including trace detection equipment such as the
systems manufactured by Thermedics Detection, for carry-on and checked baggage
screening. The FAA has made purchases of, or placed orders for the purchase of,
security equipment under this legislation, including an order to purchase $5.8
million of Thermedics Detection's EGIS systems. There can be no assurance,
however, that this legislation will not be modified to reduce the funding for
advanced explosives equipment, that the necessary appropriations will be made to
fund further purchases of advanced explosives-detection equipment contemplated
by the legislation, that trace-detection equipment such as the systems
manufactured by Thermedics Detection will be mandated, or that, even if further
appropriations are made and such equipment is mandated, any of Thermedics
Detection's explosives-detection systems will be purchased for installation at
any airports in the United States. Further, there can be no assurance that the
U.S. will mandate the widespread use of these systems after completion of the
initial purchases.
SIGNIFICANCE OF CERTAIN CUSTOMERS TO THERMEDICS DETECTION. Sales of process
detection instruments and services to bottlers licensed by The Coca-Cola Company
("Coca-Cola Bottlers") were $4,369,000, $13,939,000, $10,641,000, and
$9,974,000, for the first nine months of 1998, and in 1997, 1996, and 1995,
respectively, or 14%, 13%, 11%, and 31% of Thermedics Detection's revenues,
respectively, during such periods. In 1997, Thermedics Detection completed the
fulfillment of a mandated product-line upgrade for the Coca-Cola Bottlers.
Although Thermedics Detection anticipates that it will continue to derive
revenues from the sale of upgrades and new systems to new plants, as well as
services to the Coca-Cola Bottlers, Thermedics Detection does not expect that
revenues derived from these customers will continue at a rate comparable to
prior years. Further, Thermedics Detection intends to continue to develop and
introduce new process detection products for the food, beverage and other
markets. There can be no assurance, however, that Thermedics Detection will be
successful in the introduction of new process detection products or that any
sales of these products will be sufficient to maintain a rate of growth
equivalent to prior years.
RISKS OF THE COMPANY'S YEAR 2000 ISSUES. While the Company is attempting to
minimize any negative consequences arising from the year 2000 issue, there can
be no assurance that year 2000 problems will not have a material adverse impact
on the Company's business, operations, or financial condition. While the Company
expects that upgrades to its internal business systems will be completed in a
timely fashion, there can be no assurance that the Company will not encounter
unexpected costs or delays. Despite its efforts to ensure that its material
current products are year 2000 compliant, the Company may see an increase in
warranty and other claims, especially those related to Company products that
incorporate, or operate using, third-party software or hardware. In addition,
certain of the Company's older products, which it no longer manufactures or
sells, may not be year 2000 compliant, which may expose the Company to claims.
If any of the Company's material suppliers, vendors, or customers experience
business disruptions due to year 2000 issues, the Company might also be
materially adversely affected. The Company's research and development,
production, distribution, financial, administrative, and communications
operations might be disrupted. There is expected to be a significant amount of
litigation relating to the year 2000 issue and there can be no assurance that
the Company will not incur material costs in defending or bringing lawsuits.
14
<PAGE>
Any unexpected costs or delays arising from the year 2000 issue could have a
significant adverse impact on the Company's business, operations, and financial
condition.
INTERESTS OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON
Messrs. Peter O. Crisp, George N. Hatsopoulos, John N. Hatsopoulos, John T.
Keiser, Paul F. Kelleher and John W. Wood Jr., who are directors and/or
executive officers of the Company, are also directors and/or executive officers
of Thermo Electron.
Messrs. John N. Hatsopoulos, John T. Keiser, John W. Wood Jr., Victor L.
Poirier, Paul F. Kelleher and Nicholas T. Zervas, who are directors and/or
executive officers of the Company, are also directors and/ or executive officers
of Thermo Cardiosystems.
Messrs. Elias P. Gyftopoulos, John N. Hatsopoulos, John T. Keiser, Paul F.
Kelleher, and John W. Wood Jr., who are directors and/or executive officers of
Thermo Electron, are also directors and/or executive officers of Thermo
Cardiosystems.
See "Stock Ownership."
15
<PAGE>
STOCK OWNERSHIP
The following table sets forth the beneficial ownership of Common Stock, as
well as the common stock of Thermo Electron, the Company's parent company, and
of Thermedics Detection, Thermo Cardiosystems, Thermo Sentron and Thermo Voltek,
each a publicly traded majority-owned subsidiary of the Company, as of September
30, 1998, with respect to (i) each director, (ii) the chief executive officer of
the Company and other executive officers of the Company who during the last
completed fiscal year of the Company, met the definition of "highly compensated"
within the meaning of the Securities and Exchange Commission's executive
compensation disclosure rules, and (iii) all directors and current executive
officers as a group. In addition, the following table sets forth the beneficial
ownership of Common Stock, as of September 30, 1998, with respect to each person
who was known by the Company to own beneficially more than 5% of the outstanding
shares of Common Stock.
While certain directors and executive officers of the Company are also
directors and executive officers of Thermo Electron or its subsidiaries other
than the Company, all such persons disclaim beneficial ownership of the shares
of Common Stock owned by Thermo Electron.
<TABLE>
<CAPTION>
THERMO THERMEDICS THERMO THERMO THERMO
THERMEDICS ELECTRON DETECTION CARDIOSYSTEMS SENTRON VOLTEK
NAME(1) INC.(2) CORPORATION(3) INC.(4) INC.(5) INC.(6) CORP.(7)
- ------------------------------------------ ------------ -------------- ----------- ------------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
Thermo Electron Corporation(8)............ 24,051,621 -- -- -- -- --
The Capital Group Companies, Inc. (9)..... 1,900,000 -- -- -- -- --
T. Anthony Brooks......................... 0 0 0 0 0 0
Peter O. Crisp............................ 34,434 101,059 1,500 2,250 1,500 2,250
Paul F. Ferrari........................... 15,457 17,229 1,500 11,500 1,500 5,998
David H. Fine............................. 106,687 71,190 109,967 207 7,500 0
George N. Hatsopoulos..................... 63,681 3,564,258 21,197 11,599 17,000 0
John N. Hatsopoulos....................... 64,630 823,964 21,262 432 37,800 0
John T. Keiser............................ 81,793 192,508 17,000 56,773 19,500 0
Victor L. Poirier......................... 70,155 52,982 0 201,127 7,500 0
John W. Wood Jr........................... 157,006 269,366 38,051 46,207 35,000 96,971
Nicholas T. Zervas........................ 27,306 1,000 1,500 47,063 1,500 2,250
All directors and current executive
officers as a group (11 persons)........ 641,509 5,223,211 217,077 379,147 133,800 117,469
</TABLE>
- ------------------------
(1) Except as reflected in the footnotes to this table, shares beneficially
owned consist of shares owned by the indicated person or by that person for
the benefit of minor children, and all share ownership includes sole voting
and investment power.
(2) Shares of the Common Stock beneficially owned by Mr. Crisp, Mr. Ferrari, Dr.
Fine, Dr. G. Hatsopoulos, Mr. J. Hatsopoulos, Mr. Keiser, Mr. Poirier, Mr.
Wood, Dr. Zervas and all directors and current executive officers as a group
include 8,450, 8400, 90,300, 50,000, 50,000, 78,000, 25,700, 99,300, 8,050
and 437,200 shares, respectively, that such person or group has the right to
acquire within 60 days of September 30, 1998, through the exercise of stock
options. Shares beneficially owned by Dr. G. Hatsopoulos, Mr. J. Hatsopoulos
and all directors and current executive officers as a group include 1,635,
1,737 and 4,666 whole shares, respectively, allocated through March 1, 1998,
to their respective accounts maintained pursuant to Thermo Electron's
employee stock ownership plan (the "ESOP"), of which the trustees, who have
investment power over its assets, are executive officers of Thermo Electron.
Shares beneficially owned by Mr. Crisp, Dr. Zervas and all directors and
current executive officers as a group 7,879, 8,156 and 16,036 whole shares,
respectively, that had been allocated through July 4, 1998, to their
respective accounts maintained under the Corporation's deferred compensation
plan for directors. Shares beneficially owned by Dr. G. Hatsopoulos include
16
<PAGE>
562 shares held by Dr. G. Hatsopoulos' spouse and 92 shares allocated to his
spouse's account maintained pursuant to the ESOP. Shares beneficially owned
by Mr. Wood include 2,600 shares held in trust for the benefit of two
children. No director or executive officer beneficially owned more than 1%
of the Common Stock outstanding as of September 30, 1998; all directors and
current executive officers as a group beneficially owned 1.74% of the Common
Stock outstanding as of such date.
(3) Shares of the common stock of Thermo Electron beneficially owned by Mr.
Crisp, Dr. Fine, Dr. G. Hatsopoulos, Mr. J. Hatsopoulos, Mr. Keiser, Mr.
Poirier, Mr. Wood and all directors and current executive officers as a
group include 8,125, 54,912, 1,849,500, 762,735, 151,622, 45,225, 228,359
and 3,198,415 shares, respectively, that such person or group has the right
to acquire within 60 days of September 30, 1998, through the exercise of
stock options. Shares beneficially owned by Dr. G. Hatsopoulos, Mr. J.
Hatsopoulos and all directors and current executive officers as a group
include 2,266, 2,036 and 5,728 whole shares, respectively, allocated to
their respective accounts maintained pursuant to the ESOP. Shares
beneficially owned by Mr. Crisp and all directors and current executive
officers as a group include 46,040 whole shares allocated through July 4,
1998, to Mr. Crisp's account maintained pursuant to Thermo Electron's
deferred compensation plan for directors. Shares beneficially owned by Mr.
Ferrari include 10,062 shares held by his spouse. Shares beneficially owned
by Dr. G. Hatsopoulos include 89,601 shares held by his spouse, 168,750
shares held by a QTIP trust of which his spouse is a trustee, 39,937 shares
held by a family trust of which his spouse is the trustee and 153 shares
allocated to his spouse's account maintained pursuant to the ESOP. Shares
beneficially owned by Dr. G. Hatsopoulos also include 50,000 shares that a
family trust, of which Dr. G. Hatsopoulos' spouse is the trustee, has the
right to acquire within 60 days of September 30, 1998, through the exercise
of stock options. Except for Dr. Hatsopoulos, who beneficially owned 2.22%
of the Thermo Electron common stock outstanding as of September 30, 1998, no
director or executive officer beneficially owned more than 1% of such common
stock outstanding as of such date; all directors and current executive
officers as a group beneficially owned approximately 3.26% of the Thermo
Electron common stock outstanding as of September 30, 1998.
(4) Shares of the common stock of Thermedics Detection beneficially owned by Mr.
Crisp, Mr. Ferrari, Dr. Fine, Dr. G. Hatsopoulos, Mr. J. Hatsopoulos, Mr.
Keiser, Mr. Wood, Dr. Zervas and all directors and current executive
officers as a group include 1,500, 1,500, 99,967, 20,000, 20,000, 17,000,
20,800 1,500 and 187,267 shares, respectively, that such person or group has
the right to acquire within 60 days September 30, 1998, through the exercise
of stock options. Shares beneficially owned by Dr. G. Hatsopoulos include 57
shares held by his spouse. No director or executive officer beneficially
owned more than 1% of the Thermedics Detection common stock outstanding as
of September 30, 1998; all directors and current executive officers as a
group beneficially owned approximately 1.12% of such common stock
outstanding as of such date.
(5) Shares of the common stock of Thermo Cardiosystems beneficially owned by Mr.
Crisp, Mr. Ferrari, Mr. Keiser, Mr. Poirier, Mr. Wood, Dr. Zervas and all
directors and current executive officers as a group include 2,250, 2,250,
49,500, 158,750, 23,450, 11,300 and 247,500 shares, respectively, that such
person or group has the right to acquire within 60 days of September 30,
1998, through the exercise of stock options. Shares beneficially owned by
Dr. Zervas and all directors and current executive officers as a group
include 7,413 shares allocated through July 4, 1998, to Dr. Zervas' account
maintained pursuant to Thermo Cardiosystems' deferred compensation plan for
directors. Shares beneficially owned by Mr. Wood include 1,122 shares held
in trust for the benefit of two children. Shares beneficially owned by Dr.
Zervas include 19,000 shares held by his spouse. No director or executive
officer beneficially owned more than 1% of the Thermo Cardiosystems common
stock outstanding as of September 30, 1998; all directors and current
executive officers as a group beneficially owned approximately 1.0% of such
common stock outstanding on such date.
(6) Shares of the common stock of Thermo Sentron beneficially owned by Mr.
Crisp, Mr. Ferrari, Dr. Fine, Dr. G. Hatsopoulos, Mr. J. Hatsopoulos, Mr.
Keiser, Mr. Poirier, Mr. Wood, Dr. Zervas and all directors and current
executive officers as a group include 1,500, 1,500, 7,500, 15,000, 15,000,
17
<PAGE>
19,500, 7,500, 31,000, 1,500 and 105,000 shares, respectively, that such
person or group has the right to acquire within 60 days of September 30,
1998, through the exercise of stock options. No director or executive
officer beneficially owned more than 1% of the Thermo Sentron common stock
outstanding as of September 30, 1998; all directors and current executive
officers as a group beneficially owned approximately 1.42% of such common
stock outstanding as of such date.
(7) Shares of the common stock of Thermo Voltek beneficially owned by Mr. Crisp,
Mr. Ferrari, Mr. Wood, Dr. Zervas and all directors and current executive
officers as a group include 2,250, 2,250, 82,350, 2,250 and 89,100 shares,
respectively, that such person or group has the right to acquire within 60
days of September 30, 1998, through the exercise of stock options. The
directors and current executive officers as a group beneficially owned 1.34%
of the Thermo Voltek common stock outstanding as of September 30, 1998.
(8) Thermo Electron beneficially owned approximately 65.34% of the Common Stock
outstanding as of September 30, 1998. Thermo Electron's address is 81 Wyman
Street, Waltham, Massachusetts 02454-9046.
(9) Information regarding the number of shares of the Common Stock beneficially
owned by The Capital Group Companies, Inc. is based on the most recent
Schedule 13G of The Capital Group Companies Inc. received by the
Corporation, which reported such ownership as of December 31, 1997. The
address of The Capital Group Companies, Inc. is 333 South Hope Street, Los
Angeles, California 90071. As of December 31, 1997, The Capital Group
Companies, Inc. beneficially owned approximately 5.2% of the outstanding
Common Stock.
RECOMMENDATION
The Board of Directors believes that the proposal is in the best interest of
the Company and its Stockholders and recommends that the Stockholders vote "FOR"
the approval of the listing of 4,880,553 shares of the Company's Common Stock on
the AMEX in connection with the acquisition of TCA Holdings. If not otherwise
specified, proxies will be voted FOR approval of this proposal. Thermo Electron,
which beneficially owned an aggregate of approximately 67.7% of the outstanding
Common Stock as of the Record Date (before giving effect to the issuance of the
TMD Shares pursuant to the Merger Agreement), has sufficient votes to approve
the proposal and has indicated its intention to vote for the proposal.
OTHER ACTION
Management is not aware at this time of any other matters that will be
presented for action at the Meeting. Should any such matters be presented, the
proxies grant power to the proxy holders to vote shares represented by the
proxies in the discretion of such proxy holders.
STOCKHOLDER PROPOSALS
Proposals of Stockholders intended to be presented at the 1999 Annual
Meeting of the Stockholders of the Company must be received by the Company for
inclusion in the proxy statement and form of proxy relating to that meeting no
later than December 29, 1998.
Pursuant to recent amendments to the rules relating to proxy statements
under the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
shareholders of the Company are hereby notified that any shareholder proposal
not included in the Company's proxy materials for its 1999 Annual Meeting of
Shareholders (the "Annual Meeting") in accordance with Rule 14a-8 under the
Exchange Act will be considered untimely for the purposes of Rules 14a-4 and
14a-5 under the Exchange Act if notice thereof is received by the Company after
March 15, 1999. Management proxies will be authorized to exercise discretionary
voting authority with respect to any shareholder proposal not included in the
Company's proxy materials for the Annual Meeting unless (a) the Company receives
notice of such
18
<PAGE>
proposal by March 15, 1999, and (b) the conditions set forth in Rule
14a-4(c)(2)(i)-(iii) under the Exchange Act are met.
SOLICITATION STATEMENT
The cost of this solicitation of proxies will be borne by the Company.
Solicitation will be made primarily by mail, but regular employees of the
Company may solicit proxies personally, by telephone or telegram. Brokers,
nominees, custodians and fiduciaries are requested to forward solicitation
materials to obtain voting instructions from beneficial owners of stock
registered in their names, and the Company will reimburse such parties for their
reasonable charges and expenses in connection therewith.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by the Company with the Commission pursuant to
the Exchange Act are incorporated herein by reference:
(a) The Annual Report of the Company on Form 10-K for its fiscal year ended
January 3, 1998.
(b) The definitive Proxy Statement of the Company for its Annual Meeting of
stockholders held on June 1, 1998, as filed with the Commission April 29,
1998.
(c) The Quarterly Report of the Company on Form 10-Q for its quarter ended
April 4, 1998
(d) The Quarterly Report of the Company on Form 10-Q for its quarter ended
July 4, 1998
(e) The Quarterly Report of the Company on Form 10-Q for its quarter ended
October 3, 1998.
(f) The Current Report of the Company on Form 8-K dated March 30, 1998, as
filed with the Commission on April 3, 1998.
(g) The Current Report of the Company on Form 8-K dated June 3, 1998, as
filed with the Commission on June 3, 1998.
(h) The Current Report of the Company on Form 8-K dated August 12, 1998, as
filed with the Commission on August 13, 1998.
(i) The Current Report of the Company on Form 8-K dated September 29, 1998,
as filed with the Commission on September 30, 1998.
(j) All documents filed by the Company with the Commission pursuant to
Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the
date of this Proxy Statement and prior to the date of the Meeting shall
be deemed to be incorporated by reference in this Proxy Statement. Any
statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Proxy Statement to the extent that a
statement contained herein or in any other subsequently filed document
which also is or is deemed to be incorporated by reference modifies or
supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a
part of this Proxy Statement.
THIS PROXY STATEMENT INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT
PRESENTED HEREIN OR DELIVERED HEREWITH. COPIES OF ANY SUCH DOCUMENTS, OTHER THAN
EXHIBITS TO SUCH DOCUMENTS WHICH ARE NOT SPECIFICALLY INCORPORATED BY REFERENCE
THEREIN, ARE AVAILABLE WITHOUT CHARGE TO ANY PERSON TO WHOM THIS PROXY STATEMENT
IS DELIVERED, UPON WRITTEN OR ORAL REQUEST TO SANDRA L. LAMBERT, CLERK,
THERMEDICS INC., 81 WYMAN STREET, P.O. BOX 9046, WALTHAM, MASSACHUSETTS
02454-9046 (TELEPHONE NUMBER: (781) 622-1000)). IN ORDER TO ENSURE TIMELY
DELIVERY OF THE DOCUMENTS, ANY REQUEST SHOULD BE RECEIVED BY THE COMPANY BY
JANUARY 12, 1999.
Woburn, Massachusetts
December , 1998
19
<PAGE>
APPENDIX A
AGREEMENT AND PLAN OF REORGANIZATION
THIS AGREEMENT AND PLAN OF REORGANIZATION (this "Agreement") dated October
30, 1998 is among Thermedics Inc. ("Thermedics"), a Massachusetts corporation,
Cardio Acquisition Inc. ("Acquisition"), a Massachusetts corporation and a
wholly-owned subsidiary of Thermedics, Thermo Electron Corporation ("Thermo
Electron"), a Delaware corporation, and TMO TCA Holdings Inc. ("Holdings"), a
Massachusetts corporation and a wholly-owned subsidiary of Thermo Electron. The
parties wish to effect the acquisition of Holdings by Thermedics through a
merger of Acquisition with and into Holdings on the terms and conditions hereof.
This Agreement is intended to be a "plan of reorganization" within the meaning
of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "Code").
Accordingly, in consideration of the foregoing and the mutual
representations and covenants contained herein, the parties hereto agree as
follows:
SECTION 1
THE REORGANIZATION
1.1 THE MERGER. Upon the terms and subject to the conditions hereof, and
in accordance with the Business Corporation Law of the Commonwealth of
Massachusetts (the "BCLM"), Acquisition shall be merged with and into Holdings
(the "Merger"). The Merger shall occur at the Effective Time (as defined in
Section 1.2). Following the Merger, Holdings shall be the surviving corporation
(the "Surviving Corporation") and the separate corporate existence of
Acquisition shall cease.
1.2 EFFECTIVE TIME. As soon as practicable after the execution of this
Agreement and satisfaction or waiver of all conditions to the Merger, the
parties shall cause articles of merger (the "Articles of Merger") with respect
to the Merger to be filed and recorded in accordance with Section 78 of the BCLM
and shall take all such further actions as may be required by law to make the
Merger effective. The Merger shall be effective at such time as the Articles of
Merger are duly filed with the Secretary of State of the Commonwealth of
Massachusetts in accordance with the BCLM or at such later time as is specified
in the Articles of Merger (the "Effective Time"). The date on which the Merger
shall be effective is hereafter referred to as the "Effective Date."
1.3 CLOSING. Immediately prior to the filing of the Articles of Merger, a
closing (the "Closing") will be held at the offices of Thermo Electron
Corporation, 81 Wyman Street, Waltham, Massachusetts (or such other place as the
parties may agree) for the purpose of confirming satisfaction or waiver of all
conditions to the Merger. The date on which the Closing occurs is referred to
herein as the "Effective Date."
1.4 ARTICLES OF ORGANIZATION AND BY-LAWS. The Articles of Organization and
By-laws of Acquisition, in each case as in effect immediately prior to the
Effective Time, shall be the Articles of Organization and By-laws of the
Surviving Corporation immediately after the Effective Time.
1.5 DIRECTORS AND OFFICERS. The directors and officers of Acquisition
immediately prior to the Effective Time shall be the directors and officers of
the Surviving Corporation immediately after the Effective Time.
A-1
<PAGE>
1.6 CONVERSION OF STOCK.
At the Effective Time, by virtue of the Merger and without any action on the
part of Thermedics, Acquisition, Thermo Electron or Holdings:
(a) Each share of common stock of Holdings ("Holdings Common Stock")
outstanding immediately prior to the Effective Time (the "Holdings Shares")
shall be converted into and become the right to receive a pro rata share of
a total of 4,880,533 shares (the "Thermedics Shares") of common stock, $.10
par value per share, of Thermedics ("Thermedics Common Stock"). The
Thermedics Shares are referred to herein as the "Merger Consideration."
(b) Each share of the common stock of Acquisition ("Acquisition Common
Stock") outstanding immediately prior to the Effective Time shall be
converted into and become one validly issued, fully paid and nonassessable
share of common stock, $0.01 par value per share, of the Surviving
Corporation.
1.7 PAYMENT FOR HOLDINGS COMMON STOCK.
(a) At the Effective Time, the stock transfer books of Holdings shall be
closed and no transfers of Holdings Common Stock may be made thereafter.
Promptly after the later of (i) the listing of the Thermedics Shares for
trading on the American Stock Exchange, Inc. ("AMEX"), as contemplated by
Section 4.8 below, and (ii) the proper surrender by Thermo Electron of such
certificates representing the Holdings Shares, Thermedics shall cause its
stock transfer agent to issue and deliver to Thermo Electron a certificate
for the Thermedics Shares. It shall be a condition of such payment and
delivery that the surrendered certificate(s) be properly endorsed or
otherwise in proper form for transfer and that Thermo Electron shall pay any
transfer or other taxes required by reason of such payment or delivery or
establish, to the satisfaction of Thermedics and the Surviving Corporation
that such tax has been paid or is not applicable. The date on which all of
the conditions to the issuance of the certificate representing the
Thermedics Shares shall have been met is referred to hereinafter as the
"Payment Date."
(b) Notwithstanding the provisions of subsection (a) of this Section
1.7, in the event that, notwithstanding Thermedics' best efforts, Thermedics
is unable to obtain the approval of its stockholders of the listing of the
Thermedics Shares for trading on AMEX on or before December 31, 1999, then,
on December 31, 1999, Thermedics will pay to Holdings the sum of $75,587,000
in cash in lieu of issuing the Thermedics Shares.
1.8 ADJUSTMENTS.
(a) In the event Thermedics shall declare, pay, make or effect between
the date of this Agreement and the Payment Date, (i) any stock dividend or
other distribution in respect of the Thermedics Common Stock payable in
shares of capital stock of Thermedics, (ii) any stock split or other
subdivision of outstanding shares of Thermedics Common Stock into a larger
number of shares, (iii) any combination of outstanding shares of Thermedics
Common Stock into a smaller number of shares, (iv) any reclassification of
Thermedics Common Stock into other shares of capital stock or securities, or
(v) any exchange of the outstanding shares of Thermedics Common Stock, in
connection with a merger or consolidation of Thermedics or sale by
Thermedics of all or part of its assets, for a different number or class of
shares of stock or securities of Thermedics or for the share of the capital
stock or other securities of any other corporation, appropriate adjustment
shall be made in the number of Thermedics Shares to be issued in connection
with the Merger as may be required to put Thermo Electron in the same
position as if the record date, with respect to any such transaction or
transactions which shall so occur, had been immediately after the Payment
Date, or otherwise to carry out the intents and purposes of this Agreement.
A-2
<PAGE>
(b) In the event Thermedics shall declare, pay, make or effect between
the date of this Agreement and the Payment Date any dividend or other
distribution in respect of the Thermedics Common Stock payable in cash or
other property other than in shares of capital stock of Thermedics, then the
Thermedics Shares to be issued in connection with the Merger shall be deemed
to be outstanding as of the record date with respect to any such dividend or
distribution, and the cash or other property otherwise payable or
distributable to Thermo Electron with respect to such Thermedics Shares
shall be held by Thermedics for the benefit of Thermo Electron; and
Thermedics shall take all actions reasonably necessary to prevent such cash
or other property from being or becoming subject to any lien, security
interest or other encumbrance not for the benefit of Thermo Electron. Upon
the issuance of the Thermedics Shares to Thermo Electron pursuant to Section
1.7(a) above, such cash or other property shall likewise be distributed by
Thermedics to Thermo Electron. In no event shall Thermo Electron be entitled
to receive interest on such dividends or distributions. In the event that
Thermedics pays Thermo Electron cash consideration pursuant to Section
1.7(b) above, then such cash or other property held by Thermedics on behalf
of Thermo Electron shall not be paid or distributed to Thermo Electron and
Thermo Electron shall have no further interest therein or claim thereto.
1.9 LOST CERTIFICATES. In the event any certificate representing Thermo
Electron' Holdings Shares shall have been lost, stolen or destroyed, upon the
making of an affidavit of that fact by Thermo Electron, Thermedics shall issue
in exchange for such lost, stolen or destroyed certificate the consideration
payable in exchange therefor pursuant to this Section 1.
1.10 NO FRACTIONAL SHARES. No certificates representing fractional
Thermedics Shares shall be issued upon the surrender for exchange of the
Holdings Shares. No fractional interest shall entitle the owner to vote or to
any rights of a security holder. In lieu of a fractional share, Thermo Electron
will receive upon surrender of the Holdings Shares an amount in cash (without
interest) determined by multiplying such fraction by $15.488.
SECTION 2
REPRESENTATIONS AND WARRANTIES
OF THERMO ELECTRON AND HOLDINGS
Thermo Electron and Holdings, jointly and severally, represent and warrant
to Thermedics and Acquisition as follows. The term "knowledge," when used in
this Agreement, shall mean actual knowledge after reasonable investigation.
2.1 ORGANIZATION AND QUALIFICATION.
(a) Each of Thermo Electron and Holdings is a corporation duly
organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation and has full corporate power and authority to
own, lease and operate its assets and to carry on its business as now being
and as heretofore conducted.
(b) Thermo Electron and Holdings have previously provided to Thermedics
true and complete copies of their charter and By-laws as in effect on the
date hereof, and neither of such corporations is in default thereunder.
2.2 AUTHORITY. Each of Thermo Electron and Holdings has full right, power,
capacity and authority to execute, deliver and perform this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and
performance of this Agreement, the filing of the Articles of Merger and the
consummation of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action on the part of Thermo Electron and
Holdings. This Agreement has been duly and validly executed and delivered by
each of Thermo Electron and Holdings and constitutes the valid and binding
obligation of Thermo Electron and Holdings, enforceable against them in
accordance with the
A-3
<PAGE>
terms hereof. Neither the execution, delivery and performance of this Agreement,
the filing of the Articles of Merger nor the consummation of the transactions
contemplated hereby will (i) conflict with or result in a violation, breach,
termination or acceleration of, or default under (or would result in a
violation, breach, termination, acceleration or default with the giving of
notice or passage of time, or both) any of the terms, conditions or provisions
of the charter or By-laws of Thermo Electron or Holdings, as amended, or of any
note, bond, mortgage, indenture, license, agreement or other instrument or
obligation to which either of Thermo Electron or Holdings is a party or by which
either of Thermo Electron or Holdings or any of their respective properties or
assets may be bound or affected; (ii) result in the violation of any order,
writ, injunction, decree, statute, rule or regulation applicable to Thermo
Electron or Holdings or any of their respective properties or assets; or (iii)
result in the imposition of any lien, encumbrance, charge or claim upon any of
Thermo Electron' or Holdings' assets. Except for the filing of the Articles of
Merger, no consent or approval by, or notification to or filing with, any court,
governmental authority or third party is required in connection with the
execution, delivery and performance of this Agreement by Thermo Electron and
Holdings or the consummation of the transactions contemplated hereby.
2.3 CAPITALIZATION AND TITLE TO SHARES.
(a) The authorized capital stock of Holdings consists of 1,000 shares of
Holdings Common Stock, of which 100 shares are issued and outstanding as of
the date hereof. Thermo Electron is the record and beneficial owner of all
of such issued and outstanding shares. All of the issued and outstanding
shares of the capital stock of Holdings are duly authorized and are validly
issued, fully paid, nonassessable and free of preemptive rights.
(b) Except as set forth above, there are not as of the date hereof, and
at the Effective Time there will not be, any other shares of capital stock
of Holdings authorized or outstanding or any subscriptions, options,
conversion or exchange rights, warrants, repurchase or redemption
agreements, or other agreements or commitments obligating Holdings to issue,
transfer, sell, repurchase or redeem any shares of its capital stock or
other securities of Holdings. There are no written shareholder agreements,
voting trusts, proxies or other agreements, instruments or understandings
with respect to the voting of the capital stock of Holdings. The books and
records of Holdings, including without limitation the minute books, stock
certificate books and stock ledgers, are complete and correct and accurately
reflect the conduct of the affairs of Holdings.
2.4 OWNERSHIP OF THE CARDIO SHARES; NO OTHER ASSETS.
(a) Other than 3,335,705 shares (the "Cardio Shares") of the common
stock of Thermo Cardiosystems Inc., Holdings does not own, lease or use,
directly or indirectly, any assets or other property, whether real or
personal, tangible or intangible. All of the Cardio Shares owned by Holdings
are owned free and clear of any charges, liens, encumbrances, security
interests or adverse claims. There are no shareholder agreements, voting
trusts, proxies or other agreements, instruments or understandings with
respect to the voting of the Cardio Shares.
(b) Holdings does not, directly or indirectly, own any equity interest
in any corporation, partnership, joint venture or other entity other than
the Cardio Shares.
2.5 ABSENCE OF LIABILITIES. Holdings has no liabilities or obligations of
any nature, whether accrued, absolute, contingent or otherwise and whether due
or to become due (including without limitation, liabilities as guarantor or
otherwise with respect to obligations of others or liabilities for taxes due or
then accrued or to become due).
2.6 NO TRADE OR BUSINESS. Holdings does not engage, and since its
organization has not engaged, in any trade or business.
2.7 TAXES. Holdings has accurately prepared and duly and timely filed all
federal, state, local or foreign tax and other returns and reports ("Tax
Returns") which were required to be filed, in respect of all
A-4
<PAGE>
income, franchise, excise, sales, use, property (real and personal), payroll and
other taxes, levies, imports, duties, license and registration fees, charges or
withholdings of any nature whatsoever (collectively "Taxes"). None of the
federal, state, local or foreign Tax returns of Holdings has been audited or
examined by the governmental authority having jurisdiction. No waivers of any
statutes of limitation are in effect in respect of any Taxes.
2.8 NO CONTRACTS. There exists no contract, agreement or commitment (other
than this Agreement) to which Holdings is a party or to which Holdings or the
Cardio Shares are subject.
2.9 EMPLOYMENT MATTERS.
(a) Holdings does not employ, and since its organization has not
employed, any persons other than its officers and directors, all of whom
serve without compensation.
(b) Holdings does not maintain, and since its organization has not
maintained, any pension, profit-sharing, deferred compensation, incentive
compensation, severance pay, retirement, welfare benefit or other plan or
arrangement providing benefits to employees or retirees. Holdings has no
liability under or with respect to any employee benefit plans or
arrangements that may be maintained by any other entity.
2.10 LITIGATION OR PROCEEDINGS. Holdings is not engaged in, or a party to,
or, to the best of Thermo Electron's or Holdings' knowledge, threatened with,
any claim or legal action or other proceeding before any court, any arbitrator
of any kind or any governmental authority, nor does any basis for any claim or
legal action or other proceeding or governmental investigation exist. There are
no orders, rulings, decrees, judgments or stipulations to which Holdings is a
party by or with any court, arbitrator or governmental authority.
SECTION 3
REPRESENTATIONS AND WARRANTIES
OF THERMEDICS AND ACQUISITION
Thermedics and Acquisition, jointly and severally, represent and warrant to
Thermo Electron and Holdings as follows.
3.1 ORGANIZATION. Each of Thermedics and Acquisition is a corporation duly
organized, validly existing and in good standing under the laws of its state of
incorporation and has full corporate power and authority to own, lease and
operate its assets and to carry on its business as now being and as heretofore
conducted.
3.2 AUTHORITY. Each of Thermedics and Acquisition has full right, power,
capacity and authority to execute, deliver and perform this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and
performance of this Agreement, the filing of the Articles of Merger and the
consummation of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action on the part of Thermedics and
Acquisition. This Agreement has been duly and validly executed and delivered by
each of Thermedics and Acquisition and constitutes the valid and binding
obligation of Thermedics and Acquisition, enforceable against them in accordance
with the terms hereof. Neither the execution, delivery and performance of this
Agreement, the filing of the Articles of Merger nor the consummation of the
transactions contemplated hereby will (i) conflict with or result in a
violation, breach, termination or acceleration of, or default under (or would
result in a violation, breach, termination, acceleration or default with the
giving of notice or passage of time, or both) any of the terms, conditions or
provisions of the Articles of Organization or By-laws of Thermedics, as amended,
or Articles of Organization or By-laws of Acquisition, as amended, or of any
note, bond, mortgage, indenture, license, agreement or other instrument or
obligation to which either Thermedics or Acquisition is a party or by which
Thermedics or Acquisition or any of their respective properties or assets may be
bound or affected;
A-5
<PAGE>
(ii) result in the violation of any order, writ, injunction, decree, statute,
rule or regulation applicable to Thermedics or Acquisition or any of their
respective properties or assets; or (iii) result in the imposition of any lien,
encumbrance, charge or claim upon any of Thermedics' or Acquisition's assets.
Except for the filing of the Articles of Merger and the listing of the
Thermedics Shares for trading on the AMEX, no consent or approval by, or
notification to or filing with, any court, governmental authority or third party
is required in connection with the execution, delivery and performance of this
Agreement by Thermedics and Acquisition or the consummation of the transactions
contemplated hereby.
3.3 AUTHORIZED SHARES. The Thermedics Shares to be delivered to Thermo
Electron pursuant to this Agreement are duly authorized and, when and if so
delivered, will be validly issued, outstanding, fully paid and nonassessable.
SECTION 4
COVENANTS AND AGREEMENTS
4.1 NEGATIVE COVENANTS PENDING CLOSING. Holdings will not:
(i) DISPOSITION OF ASSETS. Sell or transfer, or mortgage, pledge or
create or permit to be created any lien on, any of the Cardio Shares;
(ii) LIABILITIES. Incur any indebtedness, obligation or liability or
enter into any contracts or commitments;
(iii) CAPITAL STOCK. Make any change in the number of shares of
Holdings' capital stock authorized, issued or outstanding or grant any
option, warrant or other right to purchase, or to convert any obligation
into, shares of Holdings' capital stock, or declare or pay any dividend or
other distribution with respect to any shares of Holdings' capital stock, or
sell or transfer any shares of its capital stock;
(iv) CHARTER AND BY-LAWS. Amend its Articles of Organization or By-laws;
or
(v) ACQUISITIONS. Make any acquisition of property.
4.2 CORPORATE EXAMINATIONS AND INVESTIGATIONS. Prior to the Effective
Time, Thermedics shall be entitled, through its employees and representatives,
to have such access to the books, records and assets of Holdings as is
reasonably necessary or appropriate in connection with its investigation of
Holdings with respect to the transaction contemplated hereby. No investigation
by Thermedics shall diminish or obviate any of the representations, warranties,
covenants or agreements of Thermo Electron or Holdings contained in this
Agreement.
4.3 EXPENSES. Whether or not the Merger is consummated, Thermedics,
Acquisition, Thermo Electron and Holdings shall bear their respective expenses
incurred in connection with the preparation, execution and performance of this
Agreement and the transactions contemplated hereby, including without
limitation, all fees and expenses of agents, representatives, counsel and
accountants.
4.4 AUTHORIZATION FROM OTHERS. Prior to the Effective Date, the parties
shall use all reasonable efforts to obtain all authorizations, consents and
permits of others required to permit the consummation of the transactions
contemplated by this Agreement.
4.5 CONSUMMATION OF AGREEMENT. Each party shall use all reasonable efforts
to perform and fulfill all conditions and obligations to be performed and
fulfilled by it under this Agreement and to ensure that to the extent within its
control or capable of influence by it, no breach of any of its respective
representations, warranties and agreements hereunder occurs or exists on or
prior to the Effective Time, all to the end that the transactions contemplated
by this Agreement shall be fully carried out in a timely fashion.
A-6
<PAGE>
4.6 FURTHER ASSURANCES. Each of the parties shall execute such documents,
further instruments of transfer and assignment and other papers and take such
further actions as may be reasonably required or desirable to carry out the
provisions hereof and the transactions contemplated hereby.
4.7 TAX-FREE REORGANIZATION. Thermedics, Acquisition, Thermo Electron and
Holdings agree that no party shall take any action directly or indirectly that
would prevent the Merger from qualifying as a tax-free reorganization under
Section 368(a) of the Code.
4.8 LISTING OF SHARES. Promptly after the Effective Date, Thermedics shall
take all action necessary in accordance with applicable law to convene a meeting
of its stockholders to be held for the purpose of approving the listing of the
Thermedics Shares for trading upon AMEX in accordance with Section 712 of AMEX's
Listing Standards, Policies and Requirements. In connection with such meeting,
Thermedics' Board of Directors shall recommend to the Thermedics stockholders
the approval of the listing of the Thermedics Shares pursuant to this Agreement.
Thermedics shall use all reasonable efforts to obtain all votes and approvals of
the Thermedics stockholders necessary for the listing of the Thermedics Shares
and all related matters under the BCLM, and its Articles of Organization and
By-laws. Thermo Electron hereby agrees to vote all of the shares of Thermedics
Common Stock held by it as of the record date of any such meeting in favor of
the listing of the Thermedics Shares and all such related matters.
4.9 PUBLIC ANNOUNCEMENTS AND CONFIDENTIALITY. Any press release or other
information to the press or any third party with respect to this Agreement or
the transactions contemplated hereby shall require the prior approval of Thermo
Electron and Thermedics, which approval shall not be unreasonably withheld,
provided that a party shall not be prevented from making such disclosure as it
shall be advised by counsel is required by law.
4.10 INDEMNIFICATION.
(A) RIGHT TO INDEMNIFICATION. Thermedics and Thermo Electron (as the
case may be, the "Indemnitee") shall be indemnified on its respective demand
made to the other (the "Indemnitor") for the full amount of all damages (as
defined below) suffered by it as a direct or indirect result of:
(i) the inaccuracy of any representation or warranty made by the
Indemnitor in or pursuant to this Agreement; and
(ii) any failure by the Indemnitor to perform any obligation or
comply with any covenant or agreement specified in this Agreement.
For the purpose of this Section 4.10, (a) references to Thermedics shall be
deemed to mean Thermedics and Acquisition; (b) the term "damages" shall be
determined and computed by reference to the effect of the compensable event on
the Indemnitee, and shall be deemed to include (i) all losses, liabilities,
expenses or costs incurred by the Indemnitee, including reasonable attorneys'
fees, and (ii) interest at a rate per annum equal to that announced from time to
time by BankBoston as its "base rate" (or the legal rate of interest, if lower)
from the date 30 days after notice of any such claim for indemnification is
given to the Indemnitor, or if an unliquidated claim, from such later date as
the claim is liquidated, to the date full indemnification is made therefor; and
(c) damages shall not include any amounts for which the Indemnitee actually
receives payment under an insurance policy, excluding self-insured amounts and
deductible amounts.
(B) INDEMNIFICATION PROCEDURES. The Indemnitee shall give the
Indemnitor notice of any claim, action or proceeding by a third party which
is reasonably likely to result in a claim for indemnification under this
Section 4.10. The Indemnitor shall have the right, at its expense, to
defend, contest, protest, settle and otherwise control the resolution of any
such claim, action or proceeding. The Indemnitee shall have the right to
participate in any such legal proceeding, subject to the Indemnitor's right
of control thereof, at the expense of the Indemnitee and with counsel
selected by the Indemnitee.
A-7
<PAGE>
(C) LIMITATIONS ON INDEMNIFICATION. Thermedics' and Thermo Electron's
rights to be indemnified pursuant to Section 4.10 shall survive the
Effective Date of this Agreement indefinitely.
4.11 CERTAIN TAX MATTERS.
(A) ALLOCATION OF CERTAIN TAXES. In the case of any Tax that is
attributable to a taxable period which begins before the Effective Date and
ends after the Effective Date, the amount of Taxes attributable to the
period prior to the Effective Date (the "Pre-Effective Period") and the
period subsequent to the Effective Date (the "Post-Effective Period") shall
be determined as follows:
(i) Thermo Electron and Thermedics agree that if Holdings is
permitted but not required under applicable foreign, state or local Tax
laws to treat the Effective Date as the last day of a taxable period,
Thermo Electron and Thermedics shall treat such day as the last day of a
taxable period.
(ii) Except to the extent provided in clause (i) of this subsection
4.11(a), in the case of ad valorem Taxes imposed on Holdings and
franchise or similar Taxes imposed on Holdings based on capital
(including net worth or long-term debt) or number of shares of stock
authorized, issued or outstanding, such Taxes shall be allocated between
the Pre-Effective Period and the Post-Effective Period based upon the
respective number of days in each such period.
(iii) Except to the extent provided in clauses (i) and (ii) of this
subsection 4.11(a), all other Taxes shall be allocated between the
Pre-Effective Period and the Post-Effective Period based upon an interim
closing of the books of Holdings as of the end of the day of the
Effective Date, and the computation of the Tax for each resulting period
as if the period were a separate taxable period; provided, however, that
in no event shall the hypothetical Tax for any period be less than zero.
(B) WAIVERS OF CARRYBACKS. Holdings and Thermo Electron agree, to the
maximum extent permitted, to elect to waive the carryback of any loss,
credit or deduction incurred in or attributable to any taxable period (or
portion thereof) after the Effective Date to any taxable period (or portion
thereof) prior to the Effective Date.
SECTION 5
CONDITIONS PRECEDENT TO THE OBLIGATIONS OF
THERMEDICS AND ACQUISITION TO CONSUMMATE THE MERGER
The obligation of Thermedics and Acquisition to consummate the Merger is
subject to the satisfaction or waiver, at or before the Effective Time, of the
following conditions:
5.1 REPRESENTATIONS, WARRANTIES AND COVENANTS. The representations and
warranties of Thermo Electron and Holdings contained in this Agreement shall be
true and correct in all material respects on and as of the Effective Time with
the same force and effect as though made on and as of the Effective Time. Thermo
Electron and Holdings shall have performed and complied in all material respects
with all covenants and agreements required by this Agreement to be performed or
complied with by them on or prior to the Effective Time and shall have obtained
all required consents and approvals. Thermo Electron and Holdings shall have
delivered to Thermedics a certificate, dated the Effective Time, to the
foregoing effect.
5.2 ARTICLES OF MERGER. Holdings shall have executed and delivered the
Articles of Merger.
5.3 CERTIFICATES. Thermo Electron and Holdings shall have furnished
Thermedics and Acquisition with such certificates of public officials and of
Thermo Electron and Holdings officers as may be reasonably requested by
Thermedics and Acquisition.
A-8
<PAGE>
SECTION 6
CONDITIONS PRECEDENT TO THE OBLIGATION OF
THERMO ELECTRON AND HOLDINGS TO CONSUMMATE THE MERGER
The obligation of Thermo Electron and Holdings to consummate the Merger is
subject to the satisfaction or waiver, at or before the Effective Time, of the
following conditions:
6.1 REPRESENTATIONS, WARRANTIES AND COVENANTS. The representations and
warranties of Thermedics and Acquisition contained in this Agreement shall be
true and correct in all material respects on and as of the Effective Time with
the same force and effect as though made on and as of the Effective Time.
Thermedics shall have performed and complied in all material respects with all
covenants and agreements required by this Agreement to be performed or complied
with by it on or prior to the Effective Time and shall have obtained all
required consents and approvals. Thermedics and Acquisition shall have delivered
to Holdings a certificate, dated the Effective Time, to the foregoing effect.
6.2 ARTICLES OF MERGER. Acquisition shall have executed and delivered the
Articles of Merger.
6.3 CERTIFICATES. Thermedics and Acquisition shall have furnished Thermo
Electron and Holdings with such certificates of public officials and of
Thermedics and Acquisition officers as may be reasonably requested by Thermo
Electron and Holdings.
SECTION 7
TERMINATION, AMENDMENT AND WAIVER
7.1 TERMINATION. This Agreement may be terminated at any time prior to the
Effective Time as follows:
(a) by Thermo Electron upon written notice to Thermedics if Thermedics
or Acquisition has materially breached any representation, warranty,
covenant or agreement contained herein and has not cured such breach within
ten (10) business days of receipt of written notice from Thermo Electron;
(b) by Thermedics upon written notice to Thermo Electron if Thermo
Electron or Holdings has materially breached any representation, warranty,
covenant or agreement contained herein and has not cured such breach within
ten (10) business days of receipt of written notice from Thermedics;
(c) by either party if any court of competent jurisdiction or United
States governmental body shall have issued an order, decree or ruling or
taken any other action restraining, enjoining or otherwise prohibiting the
Merger and such order, decree or ruling shall have become final and
nonappealable; or
(d) at any time with the written consent of Thermo Electron and
Thermedics.
7.2 EFFECT OF TERMINATION. If this Agreement is terminated as provided in
Section 7.1, this Agreement shall forthwith become void and have no effect,
except for the provisions of this Section 7.2, Section 4.3 (relating to
expenses) and Section 4.9 (relating to publicity and confidentiality) to the
extent provided therein. If this Agreement is terminated as provided in Section
7.1(c) or (d), none of the parties hereto, nor any or their directors, officers,
stockholders or affiliates, shall have any liability hereunder. Nothing
contained in this Section 7.2 shall relieve any party from liability for any
breach of this Agreement occurring before termination pursuant to Section 7.1(a)
or (b).
7.3 AMENDMENT. This Agreement may not be amended except by an instrument
signed by each of the parties hereto.
A-9
<PAGE>
7.4 WAIVER. At any time, any party hereto may (a) extend the time for the
performance of any of the obligations or other acts of any other party hereto or
(b) waive compliance with any of the agreements of any other party or any
conditions to its own obligations, in each case only to the extent such
obligations, agreements and conditions are intended for its benefit; provided
that any such extension or waiver shall be binding upon a party only if such
extension or waiver is set forth in a writing executed by such party.
SECTION 8
MISCELLANEOUS
8.1 NOTICES. All notices, requests, demands, consents and other
communications which are required or permitted hereunder shall be in writing,
and shall be deemed given when actually received or if earlier, one day after
deposit with a nationally recognized air courier or express mail, charges
prepaid or three days after deposit in the U.S. mail by certified mail, return
receipt requested, postage prepaid, addressed as follows:
If to Thermedics or Acquisition:
Thermedics Inc.
470 Wildwood Street
Woburn, Massachusetts 01888
Attention: President
With a copy to:
Thermo Electron Corporation
81 Wyman Street
Waltham, Massachusetts 02451
Attention: General Counsel
If to Thermo Electron or Holdings:
Thermo Electron Inc.
81 Wyman Street
Waltham, Massachusetts 02451
Attention: President
With a copy to:
Thermo Electron Corporation
81 Wyman Street
Waltham, Massachusetts 02451
Attention: General Counsel
or to such other address as any party hereto may designate in writing to the
other parties, specifying a change of address for the purpose of this Agreement.
8.2 SURVIVAL AND MATERIALITY OF REPRESENTATIONS. Each of the
representations, warranties and agreements made by the parties hereto shall be
deemed material and shall survive the Effective Date and the consummation of the
transactions contemplated hereby. All statements contained in any certificates
or other instruments delivered by or on behalf of the parties pursuant hereto or
in connection with the transactions contemplated hereby shall be deemed material
and shall constitute representations and warranties by the person making such
statement.
8.3 ENTIRE AGREEMENT. This Agreement, including the exhibits, the Holdings
Disclosure Schedule and the other documents referred to herein, supersedes any
and all oral or written agreements or
A-10
<PAGE>
understandings heretofore made relating to the subject matter hereof and
constitutes the entire agreement of the parties relating to the subject matter
hereof.
8.4 PARTIES IN INTEREST. All covenants and agreements, representations and
warranties contained in this Agreement made by or on behalf of any of the
parties hereto shall bind and inure to the benefit of the parties hereto, and
their respective successors, assigns, heirs, executors, administrators and
personal representatives, whether so expressed or not.
8.5 NO IMPLIED RIGHTS OR REMEDIES. Except as otherwise expressly provided
herein, nothing herein expressed or implied is intended or shall be construed to
confer upon or to give any person, firm or corporation, other than the parties
hereto, any rights or remedies under or by reason of this Agreement.
8.6 HEADINGS. The headings in this Agreement are inserted for convenience
of reference only and shall not be a part of or control or affect the meaning
hereof.
8.7 SEVERABILITY. If any provision of this Agreement shall be declared
void or unenforceable by any judicial or administrative authority, the validity
of any other provision shall not be affected thereby.
8.8 COUNTERPARTS. This Agreement may be executed in several counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
8.9 FURTHER ASSURANCES. Thermo Electron and Holdings will execute and
furnish to Thermedics and Acquisition all documents and will do or cause to be
done all other things that Thermedics may reasonably request from time to time
in order to give full effect to this Agreement and to effectuate the intent of
the parties.
8.10 GOVERNING LAW. This Agreement shall be governed by the law of the
Commonwealth of Massachusetts applicable to agreements made and to be performed
wholly within such jurisdiction, without regard to the conflicts of laws
provisions thereof.
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.]
A-11
<PAGE>
IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed as of the date first written above.
<TABLE>
<S> <C>
THERMO ELECTRON CORPORATION TMO TCA HOLDINGS INC.
By: /S/KENNETH J. APICERNO By: /S/JOHN N. HATSOPOULOS
Name: Kenneth J. Apicerno Name: John N. Hatsopoulos
Title: Treasurer Title: President
THERMEDICS INC. CARDIO ACQUISITION INC.
By: /S/KENNETH J. APICERNO By: /S/THEO MELAS-KYRIAZI
Name: Kenneth J. Apicerno Name: Theo Melas-Kyriazi
Title: Treasurer Title: President
</TABLE>
A-12
<PAGE>
PROXY
THERMEDICS INC.
PROXY FOR SPECIAL MEETING OF STOCKHOLDERS TO BE HELD JANUARY 22, 1999
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned hereby appoints John T. Keiser, Theo Melas-Kyriazi and
Kenneth J. Apicerno, or any one of them acting in the absence of the others, as
attorneys and proxies of the undersigned, with full power of substitution, for
and in the name of the undersigned, to represent the undersigned at a Special
Meeting of the Stockholders of Thermedics Inc., a Massachusetts corporation (the
"Company"), to be held on Friday, January 22, 1999 at 10:00 a.m. at the offices
of Thermo Electron Corporation, 81 Wyman Street, Waltham, Massachusetts 02454,
and at any adjournment or postponement thereof, and to vote all shares of common
stock of the Company standing in the name of the undersigned on November 27,
1998, with all of the powers the undersigned would possess if personally present
at such meeting.
CONTINUED AND TO BE SIGNED ON REVERSE SIDE
<PAGE>
PLEASE DATE, SIGN AND MAIL YOUR PROXY CARD
BACK AS SOON AS POSSIBLE!
SPECIAL MEETING OF STOCKHOLDERS
THERMEDICS INC.
JANUARY 22, 1999
Please mark your
[ X ] votes as in this
example.
1. Approve management proposal to list 4,880,553 shares of common stock,
to be issued in connection with an acquisition, on the American Stock
Exchange, Inc.
FOR [ ] AGAINST [ ] ABSTAIN [ ]
2. In their discretion on such other matters as may properly come before
the Meeting.
The shares represented by this Proxy will be voted "FOR" the proposal set forth
above if no instruction to the contrary is indicated or if no instruction is
given.
MARK HERE FOR ADDRESS CHANGE AND NOTE AT LEFT [ ]
Copies of the Notice of Meeting and of the Proxy Statement have been received by
the undersigned.
PLEASE DATE, SIGN AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED ENVELOPE.
SIGNATURE(S) DATE
----------------------------------------- ----------------------
Please sign exactly as name appears at left. When shares are held by joint
tenants, both should sign. When signing as attorney, executor, administrator,
trustee or guardian, please give full title as such. If a corporation, please
sign in full corporate name by President or other authorized officer. If a
partnership, please sign name by authorized person.
